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Abstract 
Puberty is a highly variable developmental stage marked by the development of 
secondary sex characteristics and the attainment of reproductive maturity. Variation 
during childhood developmental phases correlates with altered disease risk in adulthood; 
variation in pubertal growth and timing, in particular, correlates with adult risk for type 2 
diabetes, obesity, adverse cardiovascular heath, and hormone-dependent cancers. While 
normal variation in age at menarche (AAM) has recently been investigated in large-scale 
genome-wide association (GWA) studies, the genetic regulation of male puberty remains 
less understood. Moreover, extreme variation in pubertal timing is a common cause for 
referral to pediatric specialists, while the underlying genetic factors are largely unknown. 
  
This work aimed to identify both common and rare genetic variants influencing pubertal 
growth and timing in both sexes. Utilizing Finnish population-based samples with 
frequent height measurements across puberty, we ran GWA of growth during late puberty 
and uncovered an association for variants near LIN28B, the most robust menarche-
associated locus. Investigation of the longitudinal effects of two partly-correlated 
markers, one tagging a pubertal timing effect and one tagging an effect on adult stature, 
revealed distinct sex-specific association patterns with height growth from birth until 
adulthood. Thus, the LIN28B locus tags an important developmental regulator of both 
growth and maturational development. 
 
We then expanded to include European-wide samples within the Early Growth Genetics 
(EGG) Consortium. Genetic mapping of three pubertal growth traits revealed 9 novel 
pubertal growth variants in addition to LIN28B, 5 of which also associated with pubertal 
timing, and one which associated with childhood and adult body mass index (BMI). 
Longitudinal investigation of these variants showed diverse patterns of association with 
height growth, some of which contradicted epidemiological correlations between rapid 
prepubertal growth, advanced puberty, and reduced final adult stature. Given the complex 
relationships between these traits, tracking individual unique effects across multiple 
periods of growth may help uncover the pathways linking childhood development with 
adult health outcomes. 
 
Also within the EGG Consortium, GWA meta-analysis of Tanner genital and breast 
staging data uncovered the first robust male puberty locus on chromosome 16 near MKL2, 
a locus which also associates with advanced menarche, decreased pubertal growth, and 
shorter adult stature. Furthermore, part of the genetic architecture underlying the onset of 
puberty is shared between males and females, evidenced by the high correlation between 
menarche-advancing alleles and earlier male genital development. However, while BMI-
increasing alleles strongly correlate with advanced breast development in girls, our data 
shows that these variants play a more complex role in male puberty.  
 
  
 
 
Finally, we performed targeted sequencing of the pericentromeric region of chromosome 
2 previously robustly linked with constitutional delay of growth and puberty (CDGP), an 
extreme delay in normal pubertal timing, in multiply affected Finnish families. Analysis 
of shared low-frequency variation in genes and regulatory regions of the best functional 
candidate genes revealed 6 protein-altering variants in a single gene, DNAH6, in 10 of the 
families. However, follow-up sequencing in an additional 135 Finnish CDGP cases failed 
to provide evidence for enrichment of DNAH6 mutations compared to a large, unique set 
of SISu Finnish population controls. DNAH6 is potentially an appropriate candidate gene 
that may be involved in the regulation of steroid hormone biosynthesis by the 
cytoskeleton. This study highlights the difficulties of detecting susceptibility variants 
under a linkage signal for complex traits.   
 
Taken together, these results advance our understanding of the genetics of pubertal timing 
and development in both sexes.  However, more work is needed to understand how each 
genetic locus functions in the biology of puberty and childhood growth, and further study 
of the genetic loci highlighted in this work may help pinpoint the mechanisms that link 
the timing of this important developmental stage with adult health and risk for common 
diseases. 
 
Keywords: puberty, development, growth, genome-wide association studies (GWAS), 
targeted sequencing, constitutional delay of growth and puberty (CDGP) 
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1 Introduction 
In the news, stories report that puberty is advancing for both girls and boys. These reports 
often link the advancement of puberty to rising levels of obesity, and sometimes to 
endocrine-disrupting chemicals in the environment. While the timing of puberty has 
captured the public’s attention because of the social implications of earlier-maturing teens, 
earlier puberty also has important implications for health later in life. Yet when it comes 
down to it, the basic biology of what triggers pubertal onset, and how the timing of this 
developmental phase relates to adult health, is quite poorly understood. While it is clear 
that changing environmental factors are important for driving secular advances in puberty 
seen over the last century, it is shared genetic mechanisms that likely play a large role in 
the links between early development, pubertal timing, and health in adulthood.  
 
Puberty is a developmental stage that all adolescents go through. However, the most 
commonly used marker of puberty is age at menarche, when girls experience their first 
period. Since there is no non-invasive, easy-to-assess marker similar to menarche in boys, 
male puberty is understudied. One trait that occurs in both sexes is the pubertal growth 
spurt. The timing and magnitude of the pubertal growth spurt correlate closely with the 
central onset of puberty. Additionally, the pubertal growth spurt contributes up to 15-20% 
of final adult stature (1), so genetic variants associating with the growth spurt may also 
represent genetic height growth potential (2, 3). Finally, the pubertal growth spurt is 
associated with adult health outcomes, making it a promising avenue for the exploration of 
the genetic mechanisms underlying puberty, growth, and their associated health risks later 
in life. 
 
Another measure of pubertal development that is collected in some childhood cohort 
studies is the Tanner pubertal development scale, a 5-stage scale of male genital 
development and female breast development ranging from childlike to adult morphology. 
Both genital development and breast development begin early in puberty, closely 
following central activation in the hypothalamus. These markers are likely to tag the 
timing of pubertal onset more closely than age at menarche, since the tempo of pubertal 
development varies and because menarche occurs on average 2 years after puberty begins. 
Thus, studying these traits may reveal genetic pathways that are more closely related to 
the mechanisms which trigger central pubertal onset. 
 
Finally, the most common cause of referral to pediatric specialists is extremely early or 
delayed puberty. For pubertal delay in particular, very little is known about the molecular 
mechanisms involved. At the extreme late end of the normal population distribution, 
constitutional delay of growth and puberty (CDGP) represents a little over 2% of the 
population, and carries risks for short adult stature, decreased bone mineral density, and 
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psychosocial problems. Despite the prevalence of late growth and puberty, only a small 
handful of genetic variants are known which predispose this delay in pubertal onset. 
 
In this thesis, our primary aims were to map common variants associating with pubertal 
growth and timing in both males and females, and to localize less common variation that 
might predispose late puberty in CDGP families. Since the timing of this important 
developmental phase may have psychosocial implications and correlates with risks for 
adult obesity, type 2 diabetes, hormone-dependent cancer, and cardiovascular health, 
determining which genetic variants impact developmental trajectories between puberty 
and adverse health outcomes is an important public health question. 
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2 Literature review 
2.1 Human genetics 
 
Genetic variation contributes in some way to nearly every human ailment. Inherited 
factors, interacting with diet, environment, and lifestyle, contribute substantially to our 
risk for developing common diseases such as cancer, diabetes, and cardiovascular disease, 
which together constitute the majority of the adverse health burden in the United States 
(www.genome.gov). As genomic research advances, scientists are gaining powerful tools 
for identifying and characterizing these genetic factors, which ultimately enable medical 
researchers to improve health care at a personal level. While translating genetic findings 
from the laboratory to the clinic takes time and effort, the pace of discovery over the past 
few decades has been rapid, and genomic findings are beginning to find their way into 
medical practice. For example, genetically inherited variation can affect how a person 
responds to drug treatments, and knowledge gained from personal genetic profiles of 
variants in genes encoding drug-metabolizing enzymes and drug transporter proteins will 
allow better prediction and management of adverse drug reactions (4). As another 
example, accurate prediction of tumor phenotypes in cancer using genomic data will have 
a substantial impact on the diagnosis, personalised treatment, and prevention of cancer (5). 
These are only a couple of examples of the promise that genetic discovery holds for the 
future of medical science. 
2.1.1 A brief history 
Although the word genetics wasn’t coined until 1905, the history of genetics is often 
traced back to the work of the Augustinian friar Gregor Mendel, who worked out the basic 
laws of genetic inheritance in his studies of garden peas. Presented to the Natural History 
Society of Brünn in 1865, Mendel’s Experiments on Plant Hybridization showed that 
blocks of inheritance come in discrete units, some of which are dominantly expressed over 
other variations of the trait (6). His important discoveries remained largely 
underappreciated for nearly 40 years, but once they were rediscovered, renewed interest in 
the study of the inheritance of traits began. 
 
In the 19
th
 century, there were other important advances. In 1871, Friedrich Miescher 
discovered “nuclein,” now known as nucleic acids (7), which we now know are the 
building blocks of DNA. Chromosomes and mitosis were discovered in 1882 by Walther 
Flemming (8), providing the first glimpse at how cells replicated and divided material into 
daughter cells. Furthermore, Francis Galton developed a basic statistical model for 
inheritance, proposing that offspring receive half their inherited characteristics from each 
parent and a quarter from each grandparent (9).   
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The first half of the 20
th
 century witnessed countless more seminal discoveries. Working 
with Drosophila as a model organism, Thomas Hunt Morgan developed gene theory– that 
traits are passed from parent to offspring via discrete genes – and the principal of linkage – 
that certain alleles are somehow coupled and inherited together (10); Barbara 
McClintock’s work in maize demonstrated chromosomal crossing-over, which is the 
exchange of genetic material between homologous chromosomes (11); Avery, MacLeod, 
and McCarty showed that the agent of inheritance was deoxyribonucleic acid (DNA) and 
not protein (12); and Watson and Crick famously explained both the shape and function of 
DNA simultaneously in their double helix model, in which DNA consists of two 
backbones joined by the complimentary nucleic acid base pairs adenosine (A) – tyrosine 
(T) and cytosine (C) – guanine (G) (13). In 1961 scientists cracked the genetic code, 
showing that each codon (a triplet of bases) translates into a different amino acid (14).   
 
The pace of advancement quickened further with the refinement of the polymerase chain 
reaction (PCR) in 1985 (15), a method which uses successive cycles of heating and 
cooling to amplify a tiny DNA sample exponentially in a short timeframe. Using this 
technology, the first positionally cloned gene, CFTR, was published for cystic fibrosis in 
1989 (16). This essential tool enabled DNA technology to speed forward, spurring the 
launch of the Human Genome Project in 1990, a planned 15-year project aiming to fully 
sequence the human genome and several model organism genomes 
(http://web.ornl.gov/sci/techresources/Human_Genome/index.shtml). With competition 
heating up between the National Institutes of Health and the privately funded Celera 
Genomics in the late ‘90s, the human genome first draft was published ahead of schedule 
in 2000, and the final draft in 2003 (17, 18). In the meantime, the International HapMap 
project (http://hapmap.ncbi.nlm.nih.gov/) was launched in 2002, aiming to more fully 
understand genetic variation among individuals and populations, and was the first step 
towards identifying genetic variation relevant for common complex diseases. Also 
following the publication of the human reference genome, the Encyclopedia Of DNA 
Elements (ENCODE) and Functional Annotation of the Mammalian Genome (FANTOM) 
projects were created to provide high-quality, comprehensively annotated candidate 
functional and regulatory elements in the human and mammalian genomes for hundreds of 
different cell types, eventually providing scientists with a detailed map of how the genome 
is built and functions (19, 20).  
 
While genetics in the latter part of the 20
th
 century saw success in localizing and 
identifying single genetic mutations leading directly to disease phenotypes (“Mendelian” 
diseases), the cataloging of single nucleotide polymorphisms (SNPs) by the HapMap 
project allowed dense genotyping chips to be developed, cost-effectively resolving the 
variants present at thousands of positions along the genome in large-scale population or 
birth cohorts. The combined availability of genotype data and densely phenotyped 
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populations resulted in an explosion of phenotype-genotype associations for complex traits 
and diseases. Additionally, advancements in sequencing technology brought down both 
the cost and time needed to perform high-throughput sequencing, making whole-exome 
and whole-genome sequencing common tools for detecting variants associated with traits 
and diseases (21). Further, sequencing technology advancements have spurred large-scale 
projects like the 1000 Genomes Project (22), aiming to discover lower-frequency and 
structural variants in diverse global populations, and the International Cancer Genome 
Consortium (23), coordinating cancer genome projects worldwide. These large, globally 
collaborative projects promise to usher in a new era of scientific cooperation and 
personalized genomic medicine (21). 
2.1.2 A tour of the human genome 
 
The human genome consists of 46 chromosomes, of which 23 are inherited from each 
parent.  These consist of 22 autosomes and 2 sex chromosomes (X and Y). The nucleus of 
almost every cell in the human body contains the complete complement of chromosomes, 
which are structures made up of DNA and tightly organized by proteins. Each of our cells 
also contains a small amount of extranuclear DNA, contained in an organelle called the 
mitochondria.   
 
DNA is a chemical compound made up of a double helix consisting of two linear chains of 
nucleotide bases, adenine (A), thymine (T), guanine (G), and cytosine (C). Each base 
makes a pair with its complement in a predictable manner – A always pairs with T and G 
always pairs with C. The human genome is made up of over 3 billion base pairs, and the 
order of these base pairs determines the meaning of our genetic sequence. The minority of 
this sequence is coding, containing the genes which are instructions for making proteins, 
and other parts of the genome are non-coding, but still contain meaningful instructions, 
directing when and how genes are expressed.   
 
The publication of the complete human reference genome revealed some surprises about 
the structure of the genome. Current estimates place the number of genes in the genome at 
around 23,000, many fewer than previously thought, because the same gene can be 
transcribed into multiple different proteins and adapted for use in different biological 
contexts. The vast majority of these genes, while predicted computationally, correspond to 
orthologous genes in the mouse genome, suggesting that they are truly biologically 
relevant sequences. Many more ribonucleic acid (RNA) genes (around 6,500) and 
pseudogenes (over 12,000) also populate the human genome (21). 
 
Repetitive sequences account for at least half of the genome, a category made up of both 
simple sequence repeats and segmental duplications (SDs), or copy number variants 
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(CNVs).  The breadth and distribution of SDs came as a surprise, representing as much as 
5% of the genome in extensive inter- and intra-chromosomal duplications (21).  Specific 
SDs and CNVs are relevant for disease; for example, these have been associated with 
autism, schizophrenia, and epilepsy (24). 
 
Finally, the ENCODE project is beginning to reveal how the genome functions. A 
functional element is defined as a region of the genome encoding a defined product, like a 
protein, or containing a reproducible biochemical signature (such as transcription, or a 
specific chromatin structure). These signatures are thought to mark genomic sequences 
that have important functions, like exons (the coding part of genes), sites of RNA 
processing, or regulatory elements like promoters, enhancers, silencers, or insulators. 
While it is possible to associate certain signatures with specific functions, the ultimate 
biological function or role of a given genomic element will require functional validation 
(19) that could take decades to complete. Furthermore, biochemically active regions cover 
a larger proportion of the genome than evolutionarily conserved regions, so a combination 
of complementary approaches will be needed to sort out which elements really do function 
in human biology and disease (25). 
2.1.3 Gene mapping: methods for gene localization 
Gene mapping is the process of localizing and identifying genes that underlie inherited 
traits or diseases. Methods used for gene mapping are largely based on correlation 
between measurable features of a trait or disease (known as phenotypes) and genetic 
variants (genotypes) across the genome. Alternatively, a case/control approach may be 
used which compares the frequency of genetic variants between two groups of study 
subjects, those who have a disease (or surpass an arbitrary cut-off threshold of a 
quantitative trait) and those who do not.  
 
Since the 1980s, naturally occurring sites of genetic variation have been used as marker 
tags for gene mapping. Types of genetic variation that can contribute to variation in the 
development of a trait or disease include, but are not limited to, SNPs, or single base pairs 
that are variable in the population, CNVs, short tandem repeats, and insertions-deletions 
(indels). Early studies mapped many genes harbouring variants that caused rare Mendelian 
(single-gene) disorders (26), and newer methods allow the discovery of genes containing 
variants that associate with susceptibility to common diseases and variation in complex 
traits, or quantitative trait loci (QTL). The type and number of markers used to tag the 
genome has evolved from several hundred microsatellite tags to current “SNP chips,” 
which genotype hundreds of thousands or even millions of SNPs per sample quickly and 
cost-effectively in a single experiment. Along with imputation to fully sequenced 
reference genomes, these advances bring the number of polymorphisms per individual to 
more than ten million, densely tagging the entire genome. Additionally, the methods used 
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have developed, allowing mapping not only of rare variants with strong phenotypic 
effects, but also more common variants in genes contributing to complex, multigenic 
traits, including common diseases such as diabetes and heart disease. 
 
Approaches for mapping genes can be hypothesis-free or candidate gene-based. Two 
examples of hypothesis-free methods are linkage and association.  Linkage analysis was 
first developed in the early 20th century for mapping genes in fruit flies. With the advent 
of microsatellite markers and genome maps, this method was eventually successful for 
mapping genes in humans with the discovery of the gene for cystic fibrosis in 1989 (16) 
and for Huntington’s disease in 1993 (27). Linkage analysis follows the inheritance 
patterns of genotyped markers in families, and localizes genomic regions harbouring 
disease genes by comparing the segregation of these markers with the transmission of the 
phenotype of interest. This method unearthed genetic loci underlying many Mendelian 
diseases, as well as familial versions of common diseases.  However, linkage has met with 
more limited success as a method for detecting genes involved in polygenic or complex 
traits, except in the identification of rare, highly penetrant risk alleles in families with 
strong aggregation of specific complex diseases or alleles with large effects on 
quantitative traits (28).  
 
More recently, genome-wide association (GWA) has become widely used for QTL 
mapping.  In this method, association between common genetic variants and phenotypic 
variation in a trait of interest are detected by linear regression analysis of hundreds of 
thousands of genotyped, or millions of imputed, variants across the genome against 
phenotypic measurements. For example, in 2010, the Genetic Investigation of 
ANthropometric Traits (GIANT) Consortium published a GWA study of adult stature in 
over 180,000 individuals in which 180 common variants were associated with normal 
variation in final height (29). Other studies have used a case/control design, for example a 
recent study which reported 10 new common susceptibility loci for type 2 diabetes by 
analyzing approximately 35,000 cases and 115,000 controls of European descent (4). 
 
Hypothesis-free methods have the advantage that no previous biological knowledge is 
necessary for detecting genetic associations, and thus also provide an avenue for 
discovering unknown biological pathways and mechanisms. Indeed, candidate-gene based 
approaches have often been severely limited by the dearth of current relevant knowledge. 
Still, both approaches have vastly increased our knowledge of the genetics of both simple 
and complex traits and diseases over the past few decades.  As of November 2014, the 
Catalog of Published Genome-Wide Association Studies contained 2056 publications and 
14,854 SNPs with association data (www.genome.gov/gwastudies), and the number of 
genes with a phenotype-causing mutation was 3,299 
(http://www.omim.org/statistics/geneMap). 
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2.2 Pubertal development 
2.2.1 The physiology of puberty 
Puberty is the developmental process by which children become reproductively 
competent, involving both physiological and behavioral changes. This period of 
maturation generally spans 3-4 years, normally initiating between the ages of 9 and 14, 
with girls entering puberty an average of two years earlier than boys. At the population 
level, the timing of pubertal onset falls under a continuous distribution. Although genetic 
variation plays a major role in the timing of pubertal onset, ethnicity, health status, 
 
Figure 1. Signal integration and the hypothalamus-pituitary-gonadal axis. Reprinted from 
Sisk and Foster (2004) with permission from Nature Publishing Group. 
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nutrition, activity level, and other environmental agents can all modulate the timing of 
puberty (30).   
 
Puberty begins with a precisely orchestrated sequence of events triggered by the 
integration of multiple genetic and environmental signals by the body’s “developmental 
clock” (Figure 1) (31). While the mechanisms that integrate these various internal and 
external signals remain largely unclear, the result is activation of the hypothalamic-
pituitary-gonadal (HPG) axis, beginning with the pulsatile release of gonadotropin-
releasing hormone (GnRH) at a characteristic frequency from the hypothalamus to the 
anterior pituitary gland (32) after a period of childhood quiescence. In the pituitary, 
pulsatile GnRH stimulates the release of the gonadotropins luteinizing hormone (LH) and 
follicle stimulating hormone (FSH), which travel through the blood stream to the gonads 
(ovaries and testis), where they stimulate gonadarche, the production of mature gametes 
and sex steroids (30). Steroid hormones released from the gonads return through a positive 
feedback loop to the brain where they influence GnRH secretion and sexual behavior (33). 
This complex system of communication between the hypothalamus, pituitary gland, and 
gonads perpetuates hormonal signals, triggering the physiological changes occurring 
during pubertal development, such as the pubertal growth spurt, breast development 
(thelarche) and menarche in girls, and voice break and testicular enlargement in boys.   
 
GnRH neurons develop in the olfactory placode (nasal compartment) from progenitor cells 
and migrate into the basal hypothalamus during 6-16 weeks of gestation in humans (34). 
During this migration, many factors are likely to be important for successful development, 
including molecules related to cell-surface interactions, for example membrane receptors 
and adhesion molecules, and those related to distance communication, like 
neurotransmitters (34). The GnRH neural network and the HPG axis are partly functional 
at birth (the “minipuberty” of infancy), become restrained by unknown mechanisms, and 
are reactivated at pubertal initiation (33, 35, 36). Although secretion of GnRH is 
restrained, release of the hormone from the hypothalamus in a pulsatile fashion is 
continuous throughout childhood. During pubertal initiation, the frequency of GnRH 
release speeds up and approaches a characteristic frequency that triggers the pubertal 
development program to begin. Both transsynaptic and glial-neuronal communication are 
crucial to this change; neuronal and glial input to the GnRH neuronal network increase, 
including excitatory signals like glutamate and kisspeptin, while inhibitory input, most 
importantly from γ-aminobutyric acid (GABA) and opiatergic neurons, decreases (37). 
 
Kisspeptins are, in fact, critical for the activation of GnRH neurons during pubertal onset. 
Kisspeptins are a family of neuropeptides encoded by the KISS1 gene, and act by binding 
to the G-protein coupled receptor 54 (GPR54, otherwise known as KISS1R) (38). 
Kisspeptin is produced by neurons in the hypothalamus that have direct connections with 
GnRH neurons (39). Kisspeptin activity not only activates GnRH production, but also 
upregulates KISS1R in GnRH neurons. 
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Some physical features associated with puberty, such as pubic hair, develop independently 
of the HPG axis. Adrenarche, which is defined as the onset of dehydroepiandrosterone 
(DHEA) and DHEA-sulfate (DHEA-S) production from the adrenal gland beginning 
around age 6, results in the growth of androgen-dependent hair (pubarche) in both sexes 
prior the activation of the HPG axis. Pubarche occurs around age 8 in both sexes, although 
patterns of hair growth are sexually dimorphic (40). 
 
 
 
Figure 2. A schematic representing the timing that the majority of adolecents 
experience pubertal events. M, menarche; P.H.V., peak height velocity; P.H.2, Tanner 
pubic hair stage 2; P.H.5, Tanner pubic hair stage 5; B2, Tanner breast stage 2; B5, 
Tanner breast stage 5; G2, Tanner genital stage 2; G5, Tanner genital stage 5 Adapted 
from Brook’s Clinical Pediatric Endocrinology, 6th edition (Ed. Brook 2009) and The 
Cambridge Encyclopedia of Human Growth and Development, (Ed. Ulijaszek 1998) with 
permission. 
2.2.2 Clinical assessment of normal pubertal development 
The onset of puberty can be measured indirectly by monitoring the development of 
secondary sex characteristics, height growth velocities, and onset of menstruation (age at 
menarche, AAM). Development of breast tissue is the first clinical sign of central pubertal 
onset in girls (41), while in boys, the first physical indication is enlargement of the testis 
and reddening of the scrotal skin (42) (Figure 2). While the first menstruation is the most 
commonly assessed pubertal marker in large-scale epidemiological studies, it is a 
relatively late event in puberty, occurring on average a little over 2 years after the onset of 
breast development, and its timing varies between populations and ethnic groups. The 
onset of puberty can also be estimated by charting the pubertal growth spurt, which almost 
doubles the velocity of growth after a childhood phase of slower, more gradual growth.  
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The take-off phase of this growth spurt, as well as the period of peak height growth 
velocity (PHV) and age at which final adult height (FH) is attained, are dependent on the 
central (hypothalamic) activation of puberty, so they occur earlier in individuals maturing 
early, and are delayed in those maturing late (43). Thus, timing of the growth spurt can 
give an estimation of the timing of puberty and may prove useful as a simple phenotypic 
measure in studies aimed at detecting genes relating to pubertal timing in both sexes (44). 
 
The measurement of pubertal status can be imprecise, as puberty is a complex process that 
proceeds at different ages and at a unique tempo in each adolescent. Problems in 
ascertainment of precise pubertal phenotyping can be due to these individual differences, a 
lack of precise measurement techniques, or difficulty in obtaining permission to use the 
best measurement techniques available, which are sometimes thought to be invasive to 
one’s privacy, particularly the measurement of testicular volume (45). 
 
Several non-invasive scales have been developed to assess the stage of maturation, either 
by clinician assessment or self-assessment. The most widely used scale, the Tanner scale, 
was developed by Marshall and Tanner in the late 1960’s based on British girls and boys 
participating in the Harpenden Growth Study who were followed every 3 months during 
adolescence. The researchers took photographs of secondary sex characteristics (pubic 
hair in both sexes, breasts in girls, and genitals in boys) and classified each trait into five 
developmental stages (Figure 3, Box 1), ranging from pre-adolescent childlike 
morphology to fully mature (41, 42). Alternative assessment systems have also been 
developed, for example the Pubertal Development Scale (PDS) (45), as a way for 
adolescents to self-assess their pubertal status. 
 
The most accurate assessment of secondary sexual characteristics is likely to be performed 
by trained health professionals (46). However, clinical assessments are not always 
practically feasible, so self- or parental assessment is sometimes necessary. The validity of 
these alternative assessments remain debated, with some studies concluding that self-
assessments are accurate and agree highly with physician rating (47, 48). Other authors 
present concerns that subjects might overestimate their development at the early 
maturational stages and underestimate their development at later stages (49, 50), but 
suggest that self-assessment can be used in research where approximations of the timing 
of sexual maturation are sufficient (50). Furthermore, pubertal self-assessment is not 
reliable in obese children (51). 
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2.2.3 Heritability of pubertal timing 
The high correlation within racial and ethnic populations, within families, and between 
monozygotic twin pairs (52, 53) suggests that inherited factors play a major role in the 
variability of pubertal timing. Heritability estimates place the genetic contribution to 
pubertal variation at 50 - 80% (54–57). A recent study which examined the familial 
resemblance of age at menarche in 25,970 females estimated heritability at 57% (95% 
confidence interval 53%, 61%) (55). Heritability estimates of other markers of central 
pubertal onset were much higher; for example, a study of the pubertal height growth spurt 
in the Swedish Young Male Twins Study estimated the heritability of the age of onset of 
the growth spurt to be 91% and the age at peak height velocity to be 93% (58). These 
studies all show that genetic variation plays a substantial role in determining the timing of 
pubertal initiation. 
Figure 3. Tanner stages for male genital development (left) and female breast 
development (right). For boys, the numbers inside the ovals represent average 
testicular volume in ml, and numbers to the right represent testicular size. 
Illustrations by Michal Komorniczak. Shared under the Creative Commons 
license. 
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Box 1.  Tanner puberty scale 
Boys- genital stages 
I. Preadolescent; testes, scrotum, and penis are of approximately the same size 
and proportion as in early childhood. 
II. The scrotum and testes have enlarged, and there is a change in the texture of 
the scrotal skin. There is also some reddening of the scrotal skin. 
III. Growth of the penis has occurred, at first in length and then in breadth. There 
has been further growth of the scrotum and testes. 
IV. Penis further enlarged in length and breadth with development of glans. Testes 
and scrotum are further enlarged, with further darkening of the scrotal skin. 
V. Adult in size and shape. 
Girls- breast stages 
I. Preadolescent; elevation of papilla only. 
II. Breast bud stage; elevation of breast and papilla as a small mound, enlargement 
of areola diameter. 
III. Further enlargement of breast and areola, with no separation of their contours. 
IV. Projection of areola and papilla to form a secondary mound above the level of 
the breast. 
V. Mature stage; projection of papilla only, owing to recession of the areola to the 
general contour of the breast. 
 
Adapted with permission from Ahmed, et al (2009), Cell Press. 
 
2.2.4 Early life and environmental influences on the timing of puberty 
Environmental influences during childhood and as early as during the prenatal period also 
influence the timing of puberty. Two recent large-scale studies, the Sister Study (n = 
33,501 women (59)) and the Breakthrough Generations Study (n = 81,606 (60)), both 
found strong associations between earlier menarche and low birth weight and maternal 
smoking, a positive association with maternal age at birth, and an inverse association with 
birth order. Additionally, prenatal exposure to maternal pre-eclampsia (60), pregnancy-
related hypertensive disorder, and maternal pre-pregnancy diabetes (59) were correlated 
with advanced menarcheal timing in daughters. During infancy or childhood, not being 
breastfed and being heavy or tall at age 7 were correlated with advanced menarche (60), 
and soy formula was associated with both early and late menarche (59). Another study 
noted similar correlations between intrauterine and early postnatal growth and age at take-
off of the pubertal growth spurt and age at peak height velocity in both boys and girls (61). 
 
While overweight and obesity have received much attention in recent years, nutrition more 
specifically may also contribute to altered pubertal timing. Observational studies show that 
children with the highest intake of vegetable-based protein experienced puberty up to 7 
  
 
 
32 
months later, while children who ate more animal-based protein began puberty up to 7 
months earlier (62). High flavone or isoflavone (phytoestrogens which may perform 
hormone-like activities) intake also correlated with later breast development (63) and peak 
height velocity in girls (64). Thus, the type and quality of diet during childhood may 
influence pubertal timing and related later-life health outcomes (65). 
 
Finally, energy metabolism and physical activity in childhood also play a role in pubertal 
timing. Gymnasts are a well-known example; young female gymnasts who train 
extensively often experience delayed menarche (66). Conversely, children who exercised 
little during childhood more often had earlier menarche (60). These effects probably act 
through nutritional cues and metabolic control via peripheral hormones such as leptin and 
ghrelin that sense the body’s metabolic state and communicate this information back to the 
reproductive HPG axis (67, 68). 
2.2.5 Secular trends toward earlier maturity 
The majority of studies looking at pubertal timing trends over the last century or so have 
used menarcheal age as the standard unit of measurement. In the first half of the 20
th
 
century, AAM declined until reaching a plateau, but recent evidence suggests that the 
trend toward earlier puberty has resumed (69). In the Breakthrough Generations Study (n 
= 94,170 women), the average age at menarche declined from women born between 1908-
19 (mean AAM 13.5 yrs) and 1945-49 (mean AAM 12.6 yrs), stabilized, and then 
resumed the downward trend for girls born in 1990-93 (average AAM 12.3 yrs) (69). 
Studies of other populations show a similar trend towards earlier puberty for current 
datasets (70). 
 
Observations of earlier onset of pubertal markers other than age at menarche also show 
that puberty in general is beginning earlier, possibly as a consequence of increased 
adiposity. A study which looked at the onset of breast development in a longitudinal 
cohort noted a trend toward earlier thelarche consistent with temporal changes in body 
mass index (BMI) (71). 
 
Recent studies have also noted a possible trend in the advancement of puberty in boys. 
One study found a long-term steady decline in the age of male sexual maturity since the 
mid-eighteenth century, a trend which paralleled that seen in girls and suggests the 
presence of common environmental cues that have influenced both male and female 
pubertal timing (72). Other small studies either support (73–76) or refute (77) these 
observations in various populations, though what remains clear is that more studies are 
needed to determine whether there is a contemporary secular trend towards earlier puberty 
in boys (78). 
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2.3 Disorders of pubertal timing 
2.3.1 Early puberty 
Normal puberty can occur as early as 9 years in boys and 8 years in girls, or as early as 7 
years in non-Hispanic African American or Mexican girls (79). When the development of 
secondary sexual characteristics happens before these ages, it may be due to precocious 
puberty (Figure 4). In girls, central onset of puberty at a young age is most often 
idiopathic and accounts for 90% of precocious puberty in girls (79), while in boys there is 
more likely to be an underlying intracranial cause (80) as precocious puberty is idiopathic 
in only 50% of cases in boys (79). In idiopathic precocious puberty (IPP), the HPG axis is 
activated and puberty progresses according to a normal pattern. In contrast, in peripheral 
precocious puberty, secondary sex characteristics can develop without central 
gonadotropin release, most often caused by a gonadal or adrenal gland disorder (80). 
 
2.3.2 Delayed puberty 
Delayed puberty is defined as the absence of pubertal signs (breast or testicular 
development) after the age of 13 years in girls and 14 years in boys. Pubertal delay is 
thought to be more common in boys (though this may be due to referral bias), with 
constitutional delay of growth and puberty (CDGP) accounting for most cases of male 
pubertal delay. CDGP is characterized by a delay in height growth, skeletal maturation, 
and pubertal development, and the lack of normal adolescent growth is often the reason 
for specialist referral.  Levels of the sex hormones and gonadotropins correlate with bone 
age rather than chronological age, and spontaneous secretion of growth hormone (GH) is 
reduced, while response to GH is normal (81). 
 
CDGP represents the extreme late end of the normal pubertal spectrum, and puberty 
eventually begins spontaneously. However, delayed puberty can be difficult to distinguish 
from absent puberty due to a congenital lack of gonadotropin (hypogonadotropic 
hypogonadism, HH). Delayed puberty may also be due to chronic endocrine, metabolic, or 
systemic disorders, or simply to undernutrition (79). 
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Figure 4. Pubertal onset is a complex trait that is normally distributed in the population. 
Ages for precocious and delayed puberty are sourced from Prentice and Williams (2013). 
2.3.3 Absent puberty 
If there is a lack of pubertal initiation by age 18, it is considered pathologic (79).  
Congenital hypogonadotropic hypogonadism (CHH) is difficult to distinguish from 
CDGP, but it is characterized by the inability to produce the gonadotropic hormones LH 
and FSH in the pituitary gland (82). In this case, the gonads are normal. As there is no 
definitive test to distinguish CHH from CDGP, patients require close monitoring. In 
around 60% of CHH patients, the disorder is associated with anosmia or hyposmia (lack or 
limited sense of smell), when it is known as Kallmann syndrome (KS). In KS, the normal 
migration of GnRH neurons from the olfactory placode to the ventral hypothalamus during 
embryonic development fails. Although the precise prevalence is unknown, there is a clear 
difference in estimates between men and women. In Finland, for example, the incidence 
rate was found to be 1:30,000 men and 1:125,000 women (83). This may be partly because 
one gene associated with KS, KAL1, is located on the X chromosome. 
 
Alternatively, hypogonadism can be hypergonadotropic, with elevated levels of LH and 
FSH, indicating a lack of negative feedback to the hypothalamus (82). In this case, there is 
a failure of the gonads to produce estrogen or testosterone, and follicular maturation or 
sperm production fail to occur. 
 
In some cases, the reproductive phenotype may be quite severe, while in others, HH may 
reverse later in life (84). CHH is generally treated with lifelong hormonal therapy, but 
research indicates that for some individuals, this may not be necessary. 
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Finally, HH may be acquired rather than congenital. The cause may be tumors in the 
hypothalamus or pituitary, autoimmune diseases, or to nutritional deficit (as in anorexia 
nervosa) or intense physical activity.  Additionally, radiotherapy for the treatment of 
leukemia or brain tumors may cause hypogonadism (85). 
 
2.4 Links between puberty, childhood growth, and adult 
disease 
 
Puberty is one developmental stage along a continuum of growth events from conception 
until adulthood. There are substantial correlations between childhood body size (both in 
height and weight) and pubertal timing, as well as between pubertal timing and growth 
during the pubertal growth spurt and final adult stature. Furthermore, growth patterns and 
pubertal timing have been linked to various adult health outcomes and risks, suggesting 
that there may be shared mechanisms underlying the etiology of developmental events and 
risk of developing certain diseases.  
2.4.1 Height growth 
Postnatal height growth is a complex process, consisting of the partly overlapping phases 
of rapid infant growth, slowly diminishing childhood growth and a growth spurt during 
puberty (Figure 5). In particular, the pubertal growth spurt accounts for 15-20% of final 
adult stature (1), and represents both the activation of central puberty and local growth 
factors (2, 3). Final stature represents both genetic potential and the timing of pubertal 
growth spurt, which is dependent on the timing of the central activation of puberty. 
 
The majority of children remain at approximately the same centile of height (which is 
largely genetically determined) compared to their peers during most of their growth (43), 
except during puberty. During this time, early maturing individuals move to a higher 
centile in comparison to their peers, since they have entered the pubertal growth spurt 
earlier than others, and when they mature they tend to drop back to their pre-puberty 
centile.  In contrast, a late developer drops below their previous growth centile and catches 
up once the pubertal growth spurt occurs.  
  
The timing of puberty can also impact the total amount of pubertal growth, and thus final 
adult stature. In girls, earlier menarche, breast development, and pubertal growth spurt 
have been associated with an earlier cessation of growth and shorter adult stature (86–88). 
In boys, however, the opposite correlation has been seen, with an earlier growth spurt 
relating to slower progression through puberty and taller stature at age 18 or adulthood 
(58, 86). 
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As for adolescents with constitutional delay of growth and puberty, final height is 
sometimes significantly shorter than the mean of healthy adults (81). This is true for both 
boys and girls (81, 89–91). This reduction in final height for some CDGP patients may be 
due to a reduction in height SDS already prior to puberty (between ages 3 – 9 years), 
which does not seem to occur in the subset of patients who do reach their genetic height 
potential (92). 
 
 
Figure 5.  Height growth velocity from birth until adolescence showing rapid growth 
during infancy, a decline in height velocity over childhood, and the pubertal height growth 
spurt in girls (red) and boys (blue). 
2.4.2 Overweight and obesity 
There are well-documented links between obesity in childhood, pubertal timing, and 
height growth, indicating a complex relationship between body size and maturational 
development.  Overweight or obese children are likely to have a higher growth velocity 
and be taller in childhood, but subsequently grow less during puberty while achieving 
normal adult stature (93–96). This increase in growth appears to be GH-independent, 
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suggesting that other explanations, for example increased leptin and insulin levels, adrenal 
androgens, insulin-like growth factor (IGF)-1, IGF-binding protein-1 and GH-binding 
proteins, may explain why obese children have accelerated growth (97). In fact, GH levels 
are reduced in obese children, which is suggested to cause the growth reduction seen 
during puberty (98). Further, while there are clear correlations between increased adiposity 
and early puberty in girls, some studies in boys show that overweight/obesity may link 
with early puberty, while others link increased adiposity to pubertal delay (95, 96, 99, 
100). Some studies show that these effects are mediated via levels of pubertal hormones 
(97), but it is clear that the underlying mechanisms are complex and partly sex- specific. 
2.4.3 Altered pubertal timing and adult health risks 
Alterations in normal pubertal timing have disease risk implications, both during 
adolescence as well as for the risk of disease in adulthood.  A range of effects may be 
related to both early and late development (101). Studies of precocious puberty have noted 
the most adverse effects, including accelerated skeletal maturation and short adult height, 
early sexual debut, potential sexual abuse and difficulties such as depression and eating 
disorders (102), as well as higher risk of reproductive tract cancers (103). Premature 
adrenarche as well as early menarche are associated with higher risk of developing 
metabolic syndrome-related problems, such as obesity, type 2 diabetes, and cardiovascular 
disease (103), in addition to increased overall mortality in women (104). Additionally, 
delayed puberty can lead to stressful psychosocial effects (101), and delayed menarche is 
associated with an increased risk for bone fracture and low mineral density in the 
postmenopausal period (105).   
2.4.4 Cancer 
The timing of puberty is a risk factor for the development of hormone-dependent cancer 
later in life. For example, much attention has been focused on the potential links between 
the timing of puberty and risk for breast cancer. A recent study investigated the timing of 
pubertal stages and later life breast cancer in over 100,000 women and found that breast 
duct development may be a period of heightened susceptibility for cancer risk; 
specifically, increased breast cancer risk was associated with earlier thelarche (hazard ratio 
(HR) [95% CI] = 1.23 [1.02, 1.48], 1 [referent] and 0.80 [0.69, 0.93] for ≤10, 11-12 and 
≥13 years respectively) and earlier menarche (1.06 [0.93, 1.21], 1 [referent] and 0.78 
[0.62, 0.99] for ≤12, 13-14 and ≥15 years) (106). A correlation between menarcheal timing 
and breast cancer risk was also found in a huge study of almost 400,000 women, where 
risk of breast cancer increased by a factor of 1.05 (95% CI 1.04-1.06; P < 0.0001) for 
every year younger menarche (107). More specifically, the risk for both estrogen receptor- 
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negative and positive (ER-PR- and ER+PR+) malignancies were inversely associated with 
increasing age at menarche (108, 109).  
 
Other potentially hormone-dependent cancers have been linked to pubertal timing in both 
sexes; for example, the timing of menarche is inversely associated with ovarian cancer risk 
(oldest compared to youngest AAM, relative risk (RR) [95% CI] = 0.85 [0.75, 0.97]) 
(110).  Also, lifetime growth, specifically during puberty, is associated with testicular 
cancer risk, possibly mediated through environmental factors that affect growth over the 
lifecourse (111). 
 
The timing of menarche has further been investigated as a risk factor for other types of 
cancer that are not likely to be hormone-dependent, ie. kidney cancer (112), but such links 
are more tentative and require further study. 
2.4.5 Metabolic disorder and related disease 
Metabolic syndrome is a disorder of energy use and storage characterized by central 
obesity, high blood pressure, elevated fasting glucose levels, high serum triglycerides, and 
low high-density cholesterol (HDL) levels. Metabolic syndrome increases risk for 
developing cardiovascular disease and diabetes, and represents a major health care burden 
in the US and developed countries.   
 
Altered pubertal timing is one developmental event that has been associated with risk for 
metabolic-syndrome related disease later in life. Advanced puberty (early AAM) is 
correlated with increased risk for cardiovascular disease events, cardiovascular disease 
mortality, and mortality overall in women, and these findings were only partly mediated 
by increased adiposity. Women with AAM earlier than 12 years had a higher RR 
compared to other women of hypertension [1.13 (95% CI: 1.02-1.24)], incident 
cardiovascular disease [1.17 (1.07-1.27)], incident coronary heart disease [1.23 (1.06-
1.43)], all-cause mortality [1.22 (1.07-1.39)], cardiovascular disease mortality [1.28 (1.02-
1.62)] and cancer mortality [1.25 (1.03-1.51)], adjusted for many potential confounding 
factors such as age, smoking, physical activity, hormone use, and measures of body size 
like BMI and waist circumference (104). Early AAM has also been associated with 
increased risk for type 2 diabetes later in life in a large study of over 100,000 women, also 
partly mediated through excessive adult adiposity and increased exposure to sex 
hormones. RR of type 2 diabetes mellitus across AAM categories (≤ 11, 12, 13, 14, and ≤ 
15 years) was 1.18 (95% CI: 1.10, 1.27), 1.09 (1.02, 1.17), 1.00 (referent), 0.92 (0.83, 
1.01), and 0.95 (0.84, 1.06), respectively, in the Nurses’ Health Study (NHS) (P for trend 
< 0.0001) and 1.40 (1.24, 1.57), 1.13 (1.00, 1.27), 1.00 (referent), 0.98 (0.82, 1.18), and 
0.96 (0.78, 1.19), respectively, in NHS II (P for trend < 0.0001)  (113).  
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Until recently, studies relied on AAM to investigate the correlation between the timing of 
puberty and later development of metabolic-related disorder. Using the timing of pubertal 
growth as a proxy for pubertal timing, it has also been possible to look at the link between 
puberty and cardiometabolic health in both sexes. Specifically, earlier pubertal timing was 
associated with higher adult BMI, fasting insulin, diastolic blood pressure, and decreased 
HDL cholesterol, all of which are metabolic syndrome-related derangements, in both men 
and women (114). 
 
Common to all of these observations is that puberty is a key developmental period during 
the lifecourse which impacts health in later life. Therefore, it is critical that we gain an 
understanding of the genetic and biological mechanisms that link puberty with adult 
health, and investigate how health during adolescence might be modified to lower the risks 
of developing disease in adulthood. 
 
2.5 The genetics of pubertal timing 
2.5.1 Single-gene (Mendelian) mutations 
Single mutations in more than 21 genes have been associated with delayed or absent 
puberty (115). Some of these genes are involved in the development of the olfactory 
nervous system, with mutations typically resulting in anosmia or hyposmia (reduction in 
the ability to smell) and HH. Another set of mutations affect the kisspeptin-KISS1R 
signaling pathway, which mediates the release of GnRH by modulating the function of 
GnRH neurons and pituitary gonadotropins. These mutations together explain the cause of 
abnormal puberty in approximately 30% of cases (36). Finally, there are genetic variants 
involving HH and obesity as well as the development of the HPG axis (115). 
 
Based on the mode of inheritance, there are three types of Kallmann syndrome (KS): X-
linked (KAL1), autosomal dominant (usually with incomplete penetrance), and autosomal 
recessive (116), although occasionally digenic inheritance has also been noted (117).   
 
X-chromosomal KS is caused by mutations in the gene KAL1, encoding an extracellular 
matrix (ECM) glycoprotein called anosmin-1 that plays a key role in the migration of 
GnRH neurons and olfactory nerves to the hypothalamus. Mutations in KAL1 prevent 
GnRH neurons from entering the brain, which results in a lack of pubertal development 
and infertility (118). Several different genes have been implicated in the autosomal 
dominant form of KS. These include mutations in various fibroblast growth factor 8 
(FGF8) (119) and the fibroblast growth factor receptor 1 (FGFR1) (120). Mutations in the 
prokineticin 2 (PROK2) signaling pathway underlie recessive and compound heterozygous 
cases (121). The tyrosine kinase fibroblast growth factor receptor 1 (FGFR1) is required 
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for the development of the olfactory system and interacts with anosmin-1 (116). Although 
patients with the KAL1 form of KS have a severe phenotype with absence or extreme 
delays in pubertal onset, patients with FGFR1 mutations have a wider spectrum of 
phenotypes, some of which may also cause reversible hypogonadotropic hypogonadism. 
This suggests that modifier genes exist which have not yet been identified (84, 122). 
Mutations in the prokineticin-2 gene (PROK2) and its receptor (PROKR2) were uncovered 
in a study of KS patients, which implicates an important role for prokineticin signaling in 
olfactory and HPG axis development (115). In total, the genetic origin only around 30% of 
KS cases has been explained (117).   
 
 
Figure 6. The genetic basis underlying Kallmann syndrome (KS), hypogonadotropic 
hypogonadism (HH), and constitutional delay of growth and puberty (CDGP). Adapted 
from Gajdos, et al (2010) with permission from the authors. 
 
After GnRH neurons have completed migration, numerous genes are involved in their 
regulation. Mutations in these genes and those which regulate pituitary development and 
function can result in CHH without anosmia, for example in the gonadotropin-releasing 
hormone receptor (GNRHR) gene (123), which is estimated to account for up to 40% of all 
autosomal recessive cases of IHH and should be the first candidate gene screened in the 
clinic (124).  
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A delay in puberty diagnosed as CHH may also result from mutations in genes that affect 
gonadotropins, such as GnRHR, LH, and FSH, or in genes involved in HPG development, 
like LHX3, PROP1, HESX-1, DAX1, and SF-1.  Gonadotropins are heterodimers made up 
of an α-subunit shared by all glycoprotein hormones and a unique β-subunit. Delayed 
puberty has also been reported in patients with mutations in the FSH and LH β-subunit 
genes (116, 123). 
 
Additionally, mutations in KISS1R have been detected in HH patients (125). KISS1R is 
the G-protein coupled receptor for a family of structurally related peptides called 
kisspeptins, which are encoded by the KISS1 gene (126). The KISS1-KISS1R system is a 
critical part of the HPG axis and plays a key role in pubertal onset (125). Kisspeptin-
GPR54 signaling plays an ongoing role in the HPG axis as a regulator of LH and GnRH 
secretion as well in sex steroid feedback in adults (52). 
 
Other genes are responsible for a link between obesity and HH, including mutations in 
prohormone convertase 1 (PC1), an endopeptase required for post-translational processing 
of some prohormones and neuropeptides, which have been found in patients with obesity 
and HH (116).  
 
Finally, mutations in leptin (LEP) or the leptin receptor (LEPR) have also been seen in HH 
patients (127). In mice, leptin deficincy leads to a complex phenotype with endocrine and 
metabolic abnormalities. In one study, 3 homozygotes for a missense mutation were 
infertile due to hypothalamic-pituitary hormone deficiency, 2 of whom were adults at the 
time the paper was published. The female had primary amenhorrea, and the male had 
hypogonadism; both were morbidly obese (127).  
 
Leptin is secreted by white adipose tissue in proportion to the amount of fat stores, and 
normally acts as a satiety indicator and regulates body weight (128). Leptin also seems to 
have a permissive role in pubertal onset. For example, in women with hypothalamic 
amenorrhea due to excess exercise or nutritional deficit, leptin treatment has restored 
reproductive function (129). AAM is inversely related to the serum concentration of leptin 
(130), and, in both sexes, leptin concentration rises before the pubertal transision, followed 
by an increase in FSH, LH, and sex steroids (131). Leptin functions as a pleiotropic 
mediator in a range of neuroendocrine systems, regulating neurotransmitters such as 
polypeptide YY (PYY), which are believed to regulate GnRH secretion (116, 128). 
However, GnRH neurons do not express leptin receptors themselves (132). Recently, it 
has been shown that leptin may stimulate the secretion of kisspeptins, which then act on 
GnRH neurons (67). Additionally, a common variant near LEPR was associated with the 
timing of menarche in the general population (P = 3.5 x 10
-8
) (133), lending support to the 
notion that adequate energy storage is an important positive signal which allows puberty 
to commence.  
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In the past year, focus has shifted to the role of epigenetic mechanisms in puberty. Four 
heterozygous mutations in makorin RING-finger protein 3 (MKRN3) were found by 
whole-exome sequencing in families with central precocious puberty.  Interestingly, the 
gene lies in an imprinted region of chromosome 15 critical for Prader-Willi syndrome, and 
all of the mutations were transmitted from the affected patients’ fathers. Studies in mice 
hypothalami confirmed that the expression of the gene decreased immediately prior to 
puberty, suggesting that MKRN3 normally plays a repressive role (134). 
 
Recently, a study investigated common variants in KAL1, FGFR1, PROK2 and PROKR2 
for potential links to early or late menarche and found no association, suggesting that 
although these genes are important in puberty, they don’t play a major role in the normal 
variation of pubertal timing in the general population (135). Another study did not find 
that genetic variation in GNRH or GNRHR is a common cause of late puberty in the 
general population (115). Conversely, the most recent GWA study of AAM did find that 
common variants associated with menarche were enriched in or near genes for Mendelian 
disorders of puberty (enrichment P = 0.05) (133). These genes included MKRN3, LEPR, 
TACR3, and GNRH1. The recent GWA study needed to include over 180,000 women to 
detect these effects, so one reason why these studies came to different conclusions is likely 
that candidate studies were simply too small to detect subtle effects in the general 
population. 
2.5.2 Constitutional delay of growth and puberty: a grey area 
The genetics of constitutional delay of growth and puberty likely represents a grey area 
between rare Mendelian alterations that underlie severe pubertal delay or absence and 
more subtle variation underlying normal population variability in pubertal timing. One or 
a few genetic variants with large effect size likely drive the tail ends of normally 
distributed population traits (136). Thus far, however, very little is known about the actual 
genes which cause pubertal delay. In fact, only a handful of variants have been found in 
CDGP patients, including a homozygous mutation in GNRHR (137), several heterozygous 
point mutations in the GH secretagogue receptor gene (GHSR) (138), and a 
nonsynonymous variant in tachykinin receptor 3 (TAC3R) (139). Other genes known to 
underlie disorders of puberty (FGFR1, GNRHR, and TAC3) (140), and variation in a gene 
strongly associated with pubertal timing in the general population (LIN28B) (141), were 
not found to harbor mutations in CDGP patients. 
 
Two studies investigating the inheritance patterns of CDGP showed that many families 
displayed an apparent autosomal dominant transmission pattern for a susceptibility variant 
(142, 143). Other inheritance patters were also seen, which suggested that there are likely 
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single genes with major effects whose penetrance is affected by genetic or environmental 
modifiers (142). Subsequently, a linkage analysis located a region of linkage on the 
pericentromere of chromosome 2 (144), strongly suggesting that this region of the genome 
harbors a gene predisposing pubertal delay in multiply affected families. 
2.5.3 Common variants influencing pubertal timing in the population  
Prior to the era of GWA studies, little was known about common variants which influence 
the timing of puberty in the general population, despite the wide variability in timing and 
tempo between individuals. In 2008, a genome-wide linkage study found no evidence for 
highly penetrant common variants influencing AAM in women from Australia, The 
Netherlands, and the United Kingdom (102). In 2009, a small GWA study identified 
associated variants in the gene SPOCK, but subsequent studies failed to replicate this locus 
(145). 
 
This was the current state of knowledge about the genetics of puberty in the general 
population in 2009, when we began work on the first study included in this thesis, a gene 
mapping study of the pubertal growth spurt in several large Finnish population birth 
cohort studies. Later that same year, four studies, including between 5,000 and 25,000 
study subjects each, were published (Table 1). These studies identified a robust 
association between SNPs near LIN28B, a heterochronic regulator of developmental 
timing, and AAM (146–149), the same locus which robustly associated with pubertal 
growth in our study. Variation near the gene also associated with earlier breast 
development in girls, earlier pubic hair development and voice break in boys, a faster 
tempo of height growth and shorter adult stature in both sexes (146).  A secondary locus 
on chromosome 9 was also highlighted by these studies. 
 
Realizing that increasing the sample size would also increase power to detect common 
variants with smaller effect sizes, we joined forces with other teams interested in the 
genetics of reproductive traits within the ReproGen Consortium, which came to include 
175 researchers from 104 international research institutions. In 2010, we contributed data 
from several Finnish cohorts to a study of AAM  including 87,802 women of European 
descent, which identified 30 new loci at the genome-wide significant level, including 4 
that had previously been associated with body mass index, 3 loci in or near genes for 
energy homeostasis, and 3 loci implicated in hormonal regulation (150). A further 10 loci 
were associated at the suggestive level.   
 
The most recent large-scale GWA study of AAM published by the ReproGen consortium 
included over 180,000 women of European ancestry, from 57 contributing cohort studies 
including our contribution from the Finnish population cohorts, and mapped 123 signals at 
106 genomic loci as associated with the timing of menarche (133). All but one of the 
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previously published signals showed association with menarche in this study, and 2.71% 
of the variance in AAM was explained by these 123 SNPs in an independent sample of 
8,689 women. Interestingly, six independent signals were located in imprinted regions of 
the genome, and parent-of-origin effects were found at 14q32 which harbors the 
reciprocally imprinted genes DLK1 and MEG3, 15q11-13 in the imprinted region critical 
for Prader-Willi syndrome, and at KCNK9, representing an enrichment when compared to 
all published genome-wide significant alleles for any trait (6/123, 4.8% vs. 75/4332, 1.7%, 
P = 0.017).  
 
Studies investigating the association between the timing of menarche in non-European 
populations have revealed a large degree of overlap among distant populations.  The 
majority of these studies aimed to replicate European menarche loci in different 
populations. 8 loci were replicated in 3468 Hispanic women from the United States as part 
of the Women's Health Initiative SNP Health Association Resource (151), and 25 (60%) 
of 42 European loci also contained significant SNPs associated with the timing of 
menarche in African American women (n = 18,089) (152). One of these was the locus at 
RORA, which was suggestively associated in European women, and also associated with 
Tanner brest development stage in our third study included in this thesis. In 6,929 Chinese 
women from Shanghai, China, 32 variants had the same direction of effect as in European 
women, and 9 of them were statistically significant (153). Finally, a study of over 15,000 
Japanese women showed that SNPs at two European loci also associated at a statistically 
significant level with menarche in this population, and that six more loci were 
suggestively associated (154).  
 
Other markers of puberty, including measurements of the pubertal height growth spurt and 
secondary sex characteristics, have not been studied comprehensively in GWA studies.  
Candidate studies of the association between adult height-associated SNPs and the 
pubertal growth spurt have only revealed association for SNPs at LIN28B (155) and 
SOCS2 (156).  Consequently, very little is known about the genetic underpinnings of male 
pubertal maturation and how menarche loci relate to pubertal initiation, tempo, or other 
markers of puberty. 
 
In conclusion, it is clear that advances are being made in our understanding of the genetic 
architecture of pubertal timing in the general population, both in Europeans as well as 
other ethnicities. However, one limitation of these studies is that they are all primarily 
investigating the timing of menarche, which is a female-specific trait which occurs an 
average of two years after the onset of puberty. In the studies included in this thesis, we 
have looked at phenotypes that are present in both sexes, such as the pubertal growth 
spurt, and sexually dimorphic traits which closely follow the onset of puberty, female 
breast and male genital development. Therefore, our work has enabled the investigation of 
common variants influencing puberty in males, as well as allowing us to study the genetic 
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overlap of different phases of pubertal development, both important contributions to the 
study of pubertal genetics. 
2.5.4 Genes with common variants: their role in rare extremes of puberty 
Few studies have examined whether genes located in GWA studies contain rare variants 
which underlie extreme pubertal delay or precocity, but those which have did not find 
evidence for association. LIN28B, and its homolog LIN28A, were investigated in 
precocious (157, 158) and delayed (141) puberty, but no mutations were found. Clearly, 
more extensive studies are needed to determine whether genes with subtle effects on 
pubertal timing in the population might harbor rare mutations that would predispose a 
more extreme phenotype. 
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Table 1.   Published GWA studies to date that have investigated age at menarche 
*We have contributed data from several Finnish cohorts towards these large meta-analyses.  
Year First author Population 
Sample 
size 
Replication 
sample size 
Number of 
significant loci 
Top locus Top SNP P Effect size 
2014 Perry European* 182,416 
 
123 LIN28B rs7759938 7.8 x 10
-110
 1.4 months 
2013 Pyun Korean 3,437 
 
0 
    
2013 Tanikawa Japanese 15,495 
 
0 LIN28B rs364663 5 x 10
-7
 1.1 months 
2013 Demerath 
African 
American 
18,089 
2,850 African 
Americans, 
87,802 
Europeans 
1 ZNF483 rs10441737 4 x 10
-15
 
 
2010 Elks European* 86,142 12,813 30 LIN28B rs7759938 5 x 10
-60
 1.5 months 
2009 Ong European 4,714 16,373 1 LIN28B rs314276 4 x 10
-16
 1.7 months 
2009 Perry European 17,510 
 
2 LIN28B rs7759938 7 x 10
-9
 1.1 months 
2009 Sulem European 15,297 10,040 1 LIN28B rs314280 2 x 10
-14
 1.2 months 
2009 He European 17,438 
 
2 LIN28B rs314277 2.7 x 10
-13
 1.9 months 
2009 Liu European 477 
854 European 
siblings, 762 
Europeans, 1,387 
Chinese 
0 
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3 Study aims 
While puberty is a key developmental window associated with both early life events and 
later life health risks, the genetic mechanisms regulating pubertal timing and growth are 
understudied, especially in boys. Additionally, little is known about the genetic 
architecture underlying extreme pubertal delay, which represents the tail end of the 
population distribution and is the most common cause for referral to pediatric specialists. 
We hypothesized that many genetic variants, both common and more rare, influence 
pubertal timing. Thus, the general aim of this thesis is to address these knowledge gaps by 
identifying common genetic variants influencing pubertal growth and timing in the general 
population and less common variation influencing pubertal delay, in both sexes. 
 
Specifically, this work aimed to: 
 
1. Identify common genetic variants influencing the timing of the pubertal growth spurt 
and sexual maturation in Finnish and European-descent populations, 
 
2. Characterize the genetic relationship between the discovered variants and related 
puberty and anthropometric traits to place them into a larger developmental context, 
and 
 
3. Identify a susceptibility locus predisposing to pubertal delay in families segregating 
constitutional delay of growth and puberty. 
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4 Study design, subjects, and methods 
4.1 Study design 
 
To address Aim 1, we used a genome-wide association approach for locus discovery. We 
investigated several different models of the pubertal growth spurt in Finns (Study I) and 
Europeans (Study II), as well as the timing of sexual maturation using Tanner genital and 
breast development scale data in subjects of European descent (Study III). First, we looked 
at late pubertal growth in a GWA study including more than 4,300 Finnish population 
samples (Study I) for locus discovery and a further three Finnish population cohorts for 
replication and follow-up. In Study II, we expanded in scope to include three models of 
the pubertal growth spurt, including the take-off phase, late pubertal growth, and the total 
magnitude of the growth spurt in up to 18,700 samples of European descent. In Study III, 
we investigated Tanner breast and genital stage data to detect variants influencing the 
timing of pubertal onset in more than 11,200 European samples. 
 
For Aim 2, we characterized the effects of the discovered variants on related traits using 
regression models to study their influence on the timing of menarche (Studies I-III), 
postnatal growth (Studies I and II), pubertal growth (Study III), adult stature (Studies I-
III), and body mass index (Studies II and III).   
 
For Aim 3, we sequenced the pericentromeric region of chromosome 2 in 13 families 
segregating constitutional delay of growth and puberty contributing the most to a 
previously published, robust linkage signal (Study IV). In this study, we looked for shared 
low-frequency variants in genes and regulatory regions surrounding the best candidate 
genes from 79-124 Mb along chromosome 2. Segments of interest that passed filtering 
criteria were sequenced in an additional 135 unrelated affected probands. 
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Table 2.   Summary of the four studies included in this thesis.
Study Primary phenotype Description Sex Population 
Sample 
size 
I Late pubertal growth Difference in height SDS 14 yrs - adult males & females Finnish 
Up to 
11,573 
II Pubertal growth Height SDS at age 10  Females European 6,879 
  
 
Height SDS at age 12 males European 7,161 
  
 
Difference in height SDS 8 yrs - adult males & females European 10,799 
    Difference in height SDS 14 yrs - adult males & females European 9,228 
III Tanner puberty stage Genital stage males European 3,769 
    Breast stage females European 6,147 
IV 
Constutitional delay of 
growth and puberty Normal puberty ≥2 SD from the mean males & females Finnish 
13 families 
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4.2 Phenotypes and study subjects 
 
Studies I and II: Pubertal growth 
 
In Study I, the main phenotype investigated was the difference in height standard 
deviation (SD) score between age 14 and adult, approximating the timing of the pubertal 
growth spurt (Table 2). This study included subjects from birth cohorts collected from the 
Finnish population. The primary discovery set consisted of samples from the Northern 
Finland Birth Cohort 1966 (NFBC1966; maximum n = 5,087). Replication and follow-up 
utilized samples from the Helsinki Birth Cohort Study (HBCS; n = 1,718), the 
Cardiovascular Risk in Young Finns study (YFS; n = 2,639) and Health 2000 (H2000; n = 
2,129) (Table 3).  
 
Study II expanded upon the phenotype utilized in Study I. Because there is a large amount 
of variation in the timing and tempo of the pubertal growth spurt, an accurate model 
requires very frequent height measurements spanning a large age range. However, these 
are quite difficult to obtain in cohort studies. Also, girls enter puberty an average of 2 
years prior to boys, and thus begin their growth spurt earlier than males. In this study, we 
took these challenges into consideration and aimed to characterize pubertal growth loci by 
leveraging heterogenous height data taken at various ages during adolesence in the 
participating cohorts to maximize power. Thus, we modelled the growth spurt using three 
partly correlated measures of pubertal growth (Figure 7) that partly reflect pubertal timing 
(44). These were:  
 
1. A single height measurement (“Analysis I”) which approximated the timing of the 
take-off phase of the growth spurt: girls with height measurements available at age 10 
(±1 year) and boys with height measured at age 12 (±1 year). Sex-specific SD scores 
were calculated within each study by dividing the within-population height mean by 
the SD. 14,040 samples (7,161 males and 6,879 females) from 9 European-descent 
cohorts were included.   
2. The total amount of pubertal growth (“Analysis II”): we included individuals with a 
childhood height measurement at age 8 (±1 year) and at adulthood (≥18 years old). 
The height difference was calculated between the two measurements and sex-specific 
SD scores of this difference were calculated within each study by dividing the within-
population mean difference in height by the SD. 6 cohorts including as many as 10,799 
samples (5,043 males and 5,756 females) contributed to this analysis. 
3. The amount of late pubertal growth (“Analysis III”), approximating the timing of the 
pubertal growth spurt: similar as in Study I, the height difference was calculated 
between height at age 14 (±1 year) and at adulthood (≥18 years old) and logarithm-
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transformed sex-specific Z-scores were calculated within each study. Log 
transformation was performed prior to SD score calculation, again by dividing the 
population-specific mean log-transformed height difference by the SD. 5 cohorts with 
up to 9,228 subjects (4,282 males and 4,946 females) were included. 
 
Figure 7.    An overview of the three measures of the pubertal growth spurt utilized in Study II. 
 
Cohorts contributing to Study II were the Avon Longitudinal Study of Parents and 
Children (ALSPAC), 1958 British Birth Cohort (BC58-T1DGC and BC58-WTCCC), 
YFS, HBCS, Lifestyle- Immune System- Allergy Plus Environment and Genetics Study 
(LISAplus), NFBC1966, Queensland Institute of Medical Research (QIMR), and Western 
Australia Pregnancy Study (RAINE) (Table 3). Follow-up replication or genotyping for 
Study II was performed in the ALSPAC follow-up sample, Children’s Hospital of 
Philadelphia (CHOP), Finnish Twin Cohort Study (FTCS), Genome-Wide Population-
Based Association Study of Extremely Overweight Young Adults (GOYA), and Lifestyle- 
Immune System- Allergy study & German Infant Study on the influence of Nutrition 
Intervention plus environment and genetics (LISAplus & GINIplus; follow-up sample).  
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Analysis of early height was performed for select markers in CHOP, Copenhagen Study 
on Asthma in Childhood (COPSAC), Generation R Study (Generation R), HBCS, INMA, 
LISAplus & GINIplus, NTR, NFBC1966, Prevention and Incidence of Asthma and Mite 
Allergy birth cohort study (PIAMA), and RAINE. 
 
Study III: Sexual development 
 
In Study III, we focused on Tanner pubertal stage data (male genital stage and female 
breast stage) as our primary phenotypes. Tanner breast stage or genital stage was treated 
as a quantitative trait on a scale of 1-5. We chose separate age ranges for boys and girls at 
which the Tanner scale data were approximately normally distributed: females with a 
Tanner breast stage assessment within 10.5 - 12.5 years of age were included in the female 
discovery set (n = 6,147), and males with a Tanner genital stage assessment between 12.6 
- 15 years of age were included in the male discovery analysis (n = 3,769). 
 
In Study III, ALSPAC, BC58-T1DGC and BC58-WTCCC, YFS, Netherlands Twin 
Registry (NTR), TEENs of Attica: Genes and Environment (TEENAGE) study, and 
RAINE were included as discovery cohorts (Table 3). Follow-up was performed in 
Infancia y Medio Ambiente (INMA), Special Turku Coronary Risk Factor Intervention 
Project (STRIP), and the Leipzig Childhood Cohort (LEIPZIG).  
 
In some cohorts, Tanner stage was assessed by a clinician or trained researcher, and in 
others, Tanner stage was self-assessed using schematic drawings. Tanner stage was 
measured by self-assessment in ALSPAC, RAINE, and TEENAGE. Self-assessment or 
maternal assessment was performed in the follow-up cohort INMA. Studies in which 
Tanner stage was assessed by a medical professional were B58C-WTCCC, B58C-T1DGC, 
YFS, LEIPZIG and STRIP. In NTR, data collection was performed in several subprojects. 
 
Study IV: Constitutional delay of growth and puberty 
 
In Study IV, we investigated the region of chromosome 2 previously robustly linked with 
constitutional delay of growth and puberty in a set of Finnish families. Probands were 
drawn from patients referred to pediatric specialists due to delayed puberty who were 
identified from hospital discharge records from Helsinki, Kuopio, Tampere, and Turku 
University Hospitals as well as two municipal hospitals in southern Finland. Patients were 
included if they fulfilled diagnostic criteria for CDGP, which was defined as pubertal 
development 2 SD later than the population mean (specifically, older than 13.5 years in 
boys for Tanner genital stage II and later than 13.0 years in girls for Tanner breast stage 
II), and if other causes of pubertal delay (for example chronic illness or HH) could be 
excluded. Growth charts were also examined, and patients were included if their pubertal 
growth spurt was 2 SD later than the population average (age at takeoff of pubertal growth  
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Table 3.  Summary of the cohorts that contributed data to Studies I- III. 
Cohort 
abbreviation 
Cohort Name Ethnicity Maximum N 
(rounded) 
Study 
NFBC1966 Northern Finland Birth Cohort 1966 Finnish 4300 I, II 
HBCS Helsinki Birth Cohort Study Finnish 1700 I, II 
YFS Cardiovascular Risk in Young Finns Study Finnish 2600 I, II, III 
H2000 Health2000 Finnish 2100 I 
ALSPAC Avon Longitudinal Study of Parents and Children British 6000 II, III 
BC58-T1DGC 1958 British Birth Cohort Study British 2000 II, III 
BC58-WTCCC 1958 British Birth Cohort Study British 2000 II, III 
LISAplus Lifestyle, Immune System, Allery Plus Environment and Genetics Study German 440 II 
QIMR Queensland Institute of Medical Research European 1100 II 
RAINE Western Australia Pregnancy Study European 760 II, III 
CHOP Children's Hospital of Philadelphia European 1000 II 
FTCS Finnish Twin Cohort Study Finnish 260 II 
GOYA Genome-wide Population-Based Association Study of Extremely Overweight Young Adults Danish 180 II 
GINIplus German Infant Study on the influence of Nutrition Intervention plus Environment and Genetics German  II 
NTR Netherlands Twin Registry Dutch 600 III 
TEENAGE TEENs of Attica: Genes and Environment Greek 300 III 
INMA Infancia y Medio Ambiente Spanish 850 III 
STRIP Special Turku Intervention Project Finnish 400 III 
LEIPZIG Leipzig Childhood Cohort German 2200 III 
NFBC8586 Northern Finland Birth Cohort 1985-86 Finnish 4300 II, III 
DILGOM Dietary, Lifestyle, and Genetic determinants of Obesity and Metabolic syndrome Finnish 513 II, III 
COPSAC Copenhagen Study on Asthma in Childhood Danish 360 II 
Generation R Generation R Study Dutch, 
European 
2000 II 
PIAMA Prevention and Incidence of Asthma and Mite Allergy birth cohort study Dutch 350 II 
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later than 13.8 years in boys and 12.2 years in girls, and age at PHV later than 15.6 years 
in boys and 13.7 years in girls) (2). 
 
Invitation letters were sent to the family members of probands, and respondants were 
given structured interviews to determine their eligibility. Archived height measurements 
were used to draw growth charts, where available, and the timing of the pubertal growth 
spurt was used to determine the timing of puberty. Family members were considered to 
have CDGP if the age at take-off or PHV of the pubertal growth spurt occurred 1.5 SD or 
later than the population mean, or if they attained adult height older than 18 years for 
males or 16 years for females (144). 
 
We included the probands and parents from the 13 families that contributed most to the 
previously published linkage signal based on family-specific LOD scores in the linkage 
region on chromosome 2p13-2q13 (144) and investigated leading candidate regions in an 
additional set of 135 unrelated probands (Table 4). All participants and/or their guardian 
gave written informed consent. The study design and sample collection were approved by 
the Ethics Committee for Pediatrics, Adolescent Medicine, and Psychiatry of the Hospital 
District of Helsinki and Uusimaa.  
 
We also utilized several sets of control samples in Study IV. The first was a set of whole-
genome genotyped samples from the neurological services at the Kuopio University 
Hospital and the Helsinki University Hospital that were originally collected as controls for 
a study on intracranial aneurysm (IA controls; n = 730). These controls were collected 
from anonymous Finnish patients who gave blood for causes unrelated to IA. Genomic 
DNA was extracted from these blood samples, and genotypes were ascertained by the 
Institute for Molecular Medicine Technology Centre (Helsinki, Finland) using Illumina 
HumanCNV370-duo chips (141). 
 
Additionally, we ascertained the population frequency of sequenced variants using the 
complete 1000 Genomes (1000G) reference set, the Finnish population-specific data from 
the 1000G reference (FIN-1000G) (www.1000genomes.org/), and a unique resource of 
Finnish exome sequences (n = 3,325) from the SISu project (http://www.sisuproject.fi/), 
which are both publicly available. In the SISu project, whole-exome sequencing was done 
at the Wellcome Trust Sanger Institute using the Illumina platform. Variant recalling was 
performed jointly with ~23,000 exomes from other studies at The Broad Institute. Variants 
failing the genotype calling pipeline quality control and variants that were not within the 
bait regions of the exome capture kit were removed. Sample-wise quality control was 
performed after the removal of poor quality SNPs and individual genotypes, and variants 
with a call rate < 90 % over all samples were removed. 
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Table 4.  Summary of samples included in Study IV.
Sample set Abbreviation Ethnicity N 
Constitutional delay of growth and puberty CDGP Finnish 13 probands; 12 affected 
parents; 135 unrelated affected 
patients 
Intracranial aneurysm controls IA controls Finnish 730 
1000 Genomes controls 1000G European, African, Asian ~1000 
1000 Genomes Finnish controls FIN-1000G Finnish ~100 
Sequencing Initiative Suomi controls SISu Finnish 2028 - 3325 
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Figure 8. Pedigrees of the top 13 CDGP families contributing most to the previously 
published linkage signal. The arrow refers to the proband in each family. Filled circles 
and squares are classified as affected, while the pubertal status of grey individuals is 
unknown. #, genotyped; *, sequenced in the present study. 
 
4.3 Genotyping, imputation and quality control   
 
The same general genotyping and quality control protocol was utilized for Studies I-III 
according to standard methods. Genome-wide genotypes were obtained by individual 
cohorts using high-density SNP arrays on Illumina and Affymetrix platforms. Imputation 
was not performed for genotypes included in Study I, but was done for samples included 
in Studies II and III. Prior to imputation, SNPs with a minor allele frequency (MAF) < 
1%, call rate < 95%, and Hardy-Weinberg frequency of P < 1 x 10
-6
 were excluded. 
Samples were also excluded if they contained duplicates, excess heterozygosity, non-
European ancestry, or ambiguous sex. The MACH (159), IMPUTE (160), or BEAGLE 
(161) programs were used to impute approximately 2.5 million SNPs against HapMap 
Phase II (release 21/22). Imputed SNPs were filtered before meta-analysis to exclude 
poorly imputed SNPs (IMPUTE filter PROPER INFO < 0.4, MACH filter r
2
 < 0.3, or 
Plink INFO < 0.3). 
 
In Study IV, genotyping of the proband and both parents (trios) of the top 13 families that 
contributed the most to the previously published linkage peak was performed on the 
Illumina Infinium platform at the FIMM Technology Centre. Eight samples (the two top 
trios plus two probands from additional families) were genotyped using the HD 
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HumanCNV370-Quad Beadchip, and thirty samples (eight trios, the parents of the 
probands that were genotyped on the HumanCNV370 chip, plus one additional proband 
and their affected parent) were genotyped using the Human610-Quad BeadChip. The 
BeadStudio Genotyping Module v3.3.7 was used to call genotypes, which were then 
reviewed manually. SNPs with a success rate of < 95% were excluded. Genotypes were 
retrieved for markers spanning all autosomes and the X-chromosome. The three batches of 
genotyping had success rates of 0.96, 0.93, and 0.97, respectively. 
4.4 Genome-wide analyses 
 
Studies I-III: Genome-wide association 
 
In Study I, we performed GWA analysis of growth in height during late adolescence (the 
difference in height SDS between age 14 and adult) in NFBC1966 (n = 2,073 males and 
2,248 females). The phenotype was log-transformed prior to the calculation of sex-specific 
Z-scores. Linear regression was used in PLINK for all autosomes, assuming additive 
inheritance and including the first two principal components (PCs) as covariates, to 
account for population substructure. Males and females were meta-analyzed using a fixed-
effect model using the R package (www.r-project.org/) MetABEL. 
 
In Studies II and III, we performed genome-wide association analysis and meta-analysed 
the results across participating cohort studies. Each cohort performed genome-wide 
association analysis individually by linear regression using an additive model across 
genotyped and imputed SNPs, separately for males and females. In Study II, age at the 
adolescent measurement was included as a covariate and the first two PCs were adjusted 
within each study sample if necessary. In Study III, covariates included the first PCs if 
necessary and age at measurement (in years, to the nearest month, if available). Programs 
used to perform the GWA analyses in each cohort were MACH2QTL (159), QUICKTEST 
(162), SnpTest (163), Plink (164), or ProbABEL (160). 
 
For Study II, a fixed effects inverse-variance meta-analysis model was used to test the 
effect of each variant on early pubertal height (Analysis I), total growth during puberty 
(Analysis II), or late pubertal growth (Analysis III) separately for males and females. Sex-
specific results from each study were then meta-analyzed for each phenotype in three 
combined-gender analyses. MetABEL (160) was used for all meta-analyses. MetABEL 
corrects each individual result for its respective genomic inflation factor (λ) according to 
the genomic control method for population stratification, and an additional genomic 
control correction was applied using the overall genomic inflation factor calculated for 
each of the nine meta-analyzed results. Genome-wide significance was set at a Bonferroni-
corrected threshold of P < 1.67 x 10
-8
, to account for testing three primary phenotypes.  
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In Study III, prior to meta-analysis, cohort-specific results were filtered to exclude variants 
with a MAF < 0.03. Meta-analysis of individual cohort results was performed with 
GWAMA (165) (http://www.well.ox.ac.uk/gwama/index.shtml) for quantitative traits with 
two genomic control corrections enabled (on individual study results and then on the 
meta-analysis summary output). Gender-differentiated and gender-heterogeneity analysis 
options were also enabled. 
 
Study IV: Genome-wide characteristics of CDGP families 
 
Several genome-wide analyses were done in Study IV to explore the general amount of 
relatedness among the leading 13 CDGP probands. To compare their genetic variance 
against the IA control set, a population-based sample of random individuals from roughly 
the same geographical region in Finland, we calculated genome-wide identity-by-descent 
(IBD) among the 13 probands and the pairwise inbreeding coefficient (F) using PLINK. 
This analysis was done to confirm that there were no undetected close relationships 
between the probands’ parents. 
 
To visualize the genomic variance between the CDGP probands on a background of IA 
control subjects, the proportion of alleles shared identity-by-state (IBS) between all pairs 
of individuals was computed, and the first three PCs were plotted in multidimensional 
scaling (MDS) plots using R. 
 
4.5 Follow-up analyses of suggestive association signals 
 
Follow-up association analyses 
 
In Study I, we tested the best-associated SNP (rs7759938) and a proxy (rs314268) for 
association with pubertal growth (height SDS difference between age 15 and adult) in 
YFS (n = 1,241). We also tested amount of total phenotypic variance explained by 
rs7759938 by estimation of the regression coefficient (r
2
) in NFBC1966 with the 
normalized phenotype as the outcome in an additive regression model adjusting for the 
first 2 dimensions obtained from MDS analysis.  
 
In Study II, we followed up 22 signals from Analysis I (the single height measurement at 
age 10 in girls and 12 in boys) which associated with a P-value between 1 x 10
-5
 and 1.67 
x 10
-8
 and were not previously associated with related traits (adult stature, AAM, or BMI). 
In-silico analysis was done by ALSPAC (follow-up sample), CHOP, FTCS, and GINIplus 
(follow-up sample). Association results for a marker showing borderline significance, 
rs281379, were also provided by NTR. De novo genotyping was done for selected markers 
(success rate > 98%) from Northern Finland Birth Cohort 85-86 (NFBC8586) with 
TaqMan Pre-Designed SNP Genotyping Assays on the LightCycler 480 Real-Time PCR 
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System (Roche) according to the manufacturer’s instructions at the FIMM Technology 
Centre. Statistical analysis in the replication samples was performed similarly as in the 
discovery analyses, using PLINK (164), ProbABEL (160), or SNPtest (163), by linear 
regression for each of the 22 markers under an additive model, with age at adolescent 
measurement and correction for population substructure as optional covariates (first two 
PCs). Genomic control-corrected discovery results were meta-analyzed together with the 
individual linear regression results from contributing cohorts for each SNP, using 
MetABEL. 
 
For Study III, markers with P < 5x10
-7
 in the discovery analyses were followed up:  
rs246185 (MKL2) suggestively associated with male genital stage, and rs1149336 and 
rs1129332 (CAMTA1) suggestively associated in the male genital and female breast 
combined analysis. Genotyping of STRIP samples was performed with TaqMan Pre-
Designed SNP Genotyping Assays on the LightCycler 480 Real-Time PCR System 
(Roche) at the FIMM Technology Centre with a success rate of 0.94, 0.87, and 0.84, 
respectively. LEIPZIG sample genotyping was performed using the TaqMan Pre-Designed 
SNP Genotyping Assay run on the Applied Biosystem 7500 Real Time PCR System, 
applying the autocaller algorithm of 7500 Software V.2.0.3 with calling rates of 0.98, 
0.98, and 0.93, respectively. Association analyses of genotype with Tanner stage were 
performed by each contributing cohort, and meta-analysed together with the primary 
discovery summary statistics using linear regression in PLINK (164). 
 
In Study III, we also repeated the female Tanner breast stage analysis with a BMI cutoff to 
exclude the possibility of obesity interfering with breast stage measurements. Females in 
the lower 80
th
 percentile of BMI were included from the contemporary cohorts ALSPAC, 
YFS, and NTR (n = 2,637). The top SNPs from the LIN28B locus were then extracted and 
compared to the original female meta-analysis results. 
 
Conditional analysis 
 
In Study II, several of our leading signals overlapped previously published adult height, 
AAM, or BMI loci. To determine whether our leading signals represented independent 
effects on growth during puberty, we performed conditional analysis by linear regression 
using an additive model on the primary pubertal growth phenotypes, adjusting each 
marker (imputed genotype dose) for the previously reported marker. Age at adolescent 
measurement (where available) and optional adjustment for population substructure were 
included as covariates. 
 
CNV analysis of 16p11.2 
 
The leading novel signal (rs4788196 at MAPK3) in Study II fell in a region of the genome 
where rare recurrent CNVs have been associated with early onset obesity (166, 167). 
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Thus, we explored whether CNVs could explain the association signal between growth 
during puberty and the leading variant, since advanced pubertal timing has also been 
correlated with increased pre-pubertal body mass. CNVs were genotyped using signal 
intensity distributions and B-allele frequencies of the genotyping probes with PennCNV 
software (168) and adjusted for genomic waves according to genomic GC content (169). 
The CNV scan was performed for 2,310 individuals in YFS and 4,931 subjects in 
NFBC1966 (170). 
 
1000 Genomes imputation 
 
In Study III, the leading signal associated with male genital stage (rs246185 at MKL2) also 
fell on chromosome 16. To fine map this locus in an attempt to further refine the 
association signal, we imputed against 1000 Genomes data in ALSPAC, YFS, RAINE, 
and TEENAGE. Imputation was performed with IMPUTE (171), MaCH (159) or Minimac 
(172). Association analysis was then performed in each cohort using SNPtest V2 (171), 
MACH2QTL (159), or QUICKTEST (162). After cohort-specific association, the results 
were filtered based on imputation quality (PROPER INFO <0.4, r2<0.3, or INFO < 0.3), 
and meta-analysis was performed using GWAMA (165). The 1 Mb region surrounding 
rs246185 was extracted from the complete chromosome 16 results. 
 
Functional investigation of variants in LD 
 
Also in Study III, we investigated variants that were in high linkage disequilibrium (LD) 
with rs246185 for evidence of involvement in transcription factor (TF) binding sites. SNPs 
nearby rs246185 were extracted from the 1000 Genomes Pilot I dataset in the online 
SNAP proxy search tool (http://www.broadinstitute.org/mpg/snap/ldsearch.php) with an r
2
 
threshold of 0.6. The resulting 12 SNPs (plus rs246185) were then entered into 
RegulomeDB (173) (http://www.regulome.stanford.edu/index), which annotates variants 
with known and predicted regulatory elements, including regions of DNAase 
hypersensitivity, transcription factor binding sites, and biochemically characterized 
promoter regions that affect transcription, in intergenic genomic regions. These data are 
sourced from public datasets. 
 
Expression quantitative trait loci (eQTLs) 
 
Expression quantitative trait loci (eQTLs) were investigated in Studies II-III to attempt to 
link the leading GWA signals to nearby gene expression levels. For Study II, we queried 
significant SNPs from the Dietary, Lifestyle, and Genetic determinants of Obesity and 
Metabolic syndrome (DILGOM) study (174). In this study, whole blood was extracted 
from 518 unrelated individuals and genotyped on the Ilumina 610-Quad SNP array. In 
parallel, mRNA expression was quantified with Illumina HumanHT-12 Expression 
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BeadChips, and the association between transcript expression levels and each SNP was 
tested by linear regression. 
 
In Study III, whole blood eQTLs were also queried from the DILGOM study (174), NTR, 
and the Netherlands Study of Depression and Anxiety (175, 176). GENEVAR (177) 
(GENe Expression VARiation; http://www.sanger.ac.uk/resources/software/genevar/) was 
used to look up data on rs246185 from lymphoblastoid cell lines (178, 179), skin, and 
adipose tissue (179). 
 
4.6 Pathway analyses 
 
We performed pathway analyses in Studies II-III to look for biological pathways common 
to genes nearby the leading associated signals. For Study II, we entered the nearest gene to 
all signals at P < 1x10
-4
 (one per locus) into the g:Profiler Gene Group Functional Profiler 
tool (g:GOSt) (180). This online tool queries databases of biological pathways for 
enrichment of user-entered genes. For the single height analysis (Analysis I), we also 
entered MAPK3 because the gene was implicated by eQTL evidence to be functionally 
relevant, which brought the total of signals queried to 93, corresponding to 0.0003% of all 
discovery signals for Analysis I. We additionally ran gene set enrichment (GSE) analysis 
using MAGENTA (181), which calculates a P-value for each gene in the genome based on 
GWA results, and then searches biological databases for pathways showing an enrichment 
of genes with lower than expected P-values. There were no significant findings for 
Analyses II and III. 
 
In Study III, GSE analysis was performed using MAGENTA (181) on the results for males 
and females separately and combined. For both Studies II and III, default values were used 
for the number of gene set permutations, for the upstream and lower boundaries 
surrounding each gene, and for the gene set size limits. GSE analyses were run for both 
75
th
 and 95
th
 percentiles, and genes in the HLA region were removed prior to analysis. 
Pathways were reported that had a false discovery rate (FDR) of ≤ 0.05 and a nominal 
GSE P < 1x10
-3
.
 
4.7 Association analyses of AAM, height, and BMI 
 
Pubertal timing (timing of the growth spurt and menarche) 
 
In Studies I-II, our primary phenotypes were not directly pubertal traits, but of measures of 
the growth spurt that occurs during puberty, which reflects both pubertal timing and 
genetic height growth potential. Thus, it was important to assess the relevance of pubertal 
growth-associated variants for their effect on more direct assessments of pubertal timing.   
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In Study I, we first investigated whether markers at the LIN28B locus associated with late 
pubertal growth reflected an effect on the timing of the pubertal growth spurt. To do this, 
we looked at the association between the leading markers and growth during early and 
mid-puberty (9-12 years and 12-14/15 years in YFS and NFBC1966, and 9-12 years in 
HBCS).  Additionally, we investigated the association between rs7759968 and AAM in 
the Finnish datasets (n = 4,379 Finns). Finally, we performed multiple regression analysis 
including rs7759938 and height growth during early puberty (9-12 years old) to determine 
whether the pubertal height growth and menarche effects were independent.  
 
In Study II, the leading signals not previously implicated in the timing of menarche were 
queried from in silico meta-analysis data of 87,802 women published by the ReproGen 
Consortium (150). 
 
Additionally, in Study III, the effects of the male genital stage-associated marker rs246185 
on female puberty and pubertal growth were estimated by extracting this variant from the 
female Tanner GWA analysis results as well as from previously published GWA studies 
on age at menarche by the ReproGen Consortium (150) and three pubertal height growth 
phenotypes (182). 
 
Height and BMI 
 
In Study I, an association to final height was previously published at two LIN28B markers 
only partly correlated with each other (rs314277 and rs314268, r
2
 = 0.26). rs314268 
overlaps with a pubertal timing effect (r
2
 = 0.94 with rs7759938), thus potentially 
mediating an adult height effect through the timing of the pubertal growth spurt. In the 
Finnish cohorts, we tested for two separate height effects by considering the effect of 
rs7759938 and rs314277 separately and then by including both markers into a regression 
model against final adult stature. Finally, we performed multiple regression analysis 
including both SNPs, sex, and all possible interactions into the model. We then plotted the 
marker-specific beta and SE from the multiple regression analyses of height across the 
complete growth trajectory from infancy to adulthood, including both markers in the 
models (standardized height at 1-year intervals between ages 1-12, standardized height at 
age 14, and adult stature in NFBC1966 and HBCS) to visualize the effects of these 
markers across postnatal growth. 
 
Similarly, in Study II, eight of the leading loci were previously identified as associated 
with adult stature (29) and one was previously associated with BMI (183, 184). To 
characterize their effects longitudinally across postnatal life, we divided height or BMI 
measurements from childhood to adulthood into 6 age bins: 1) Pre-puberty (6.5 - 8.5 years 
old), 2) early puberty (8.6 - 10.5 yrs old), 3) mid-puberty for females (10.6 - 12.5 yrs old), 
4) mid-puberty for males (12.6 - 14.5 yrs old), 5) late puberty (14.6 - 17.5 yrs old) and 
finally 6) adult (> 17.6 yrs old).  In each contributing cohort, each marker of interest 
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(imputed genotype dosage) was tested for association with height or BMI SDS for males 
and females separately for all age bins available, using linear regression with an additive 
model and adjustment for exact age at measurement (to the nearest month), along with 
correction for population stratification if needed. One measurement was included per 
subject per bin, with the age closest to the mean used when more than one measurement 
was available. Summary statistics were meta-analyzed like the primary analyses in each 
age bin, separately for males and females, for both height and BMI distinctly. Effect sizes 
were plotted against age to visualize their effects longitudinally across postnatal growth 
for the 10 significantly associated pubertal growth SNPs. 
 
Additionally, in Study II we investigated the association with early growth for five 
menarche-associated pubertal growth variants. Cohorts that contributed had height 
measurements available at 1, 2, 3, or 4 years old. Length was measured at 12 months 
(range 6-18 months) and height was measured at 24 (range 18-30), 36 (range 30-42) and 
48 (range 42-54) months. When multiple measurements per individual were available, 
those closest to 12, 24, 36 or 48 months were used. Sex- and age-adjusted SD scores were 
calculated in each study using Growth Analyser 3.0 (Dutch Growth Research Foundation, 
Rotterdam, the Netherlands) (185). The association between each marker genotype and 
length or height SDS was assessed using linear regression for males and females 
separately, assuming an additive model. Imputed genotypes were used where directly-
assayed genotypes were unavailable, and meta-analysis of the within-cohort results was 
done using the inverse-variance method. A fixed-effects model was assumed, using RMeta 
in R. 
 
For Study III, the leading male genital signal rs246185 was queried from the previously 
published GIANT-consortium study on adult stature (29).  
 
Overlap of published menarche and BMI SNPs with Tanner staging 
 
In Study III, we looked at the association of published menarche and BMI loci in our 
Tanner pubertal staging data. 32 previously published menarche loci, 10 possible 
menarche loci (150), and 2 pubertal growth loci with evidence for menarche-association 
from Study II were extracted from the Tanner GWA discovery analysis results sets, for 
both males and females separately and combined. Also, we extracted 31 SNPs associated 
with adult (183) and/or childhood (184) BMI from the three Tanner analysis results. We 
then plotted the menarche effect size against the Tanner effect size for the puberty-
advancing allele for males and females both separately and combined. Similarly, we 
plotted the BMI effect size against the Tanner effect size for the BMI-increasing allele for 
males and females both separately and combined. Finally, we calculated the correlation 
between the menarche and Tanner effect sizes, and between the BMI and Tanner effect 
sizes for the loci in each plot, for both males and females separately and combined. 
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4.8 Sequencing (Study IV) 
 
In Study IV, we performed targeted sequencing of the pericentromeric region (79,171,971 
– 124,250,162 Mb; genome build 37) of chromosome 2 in 13 CDGP probands and their 
suspected affected parent (n = 26). Sequencing was done on the Illumina HiSeq2000 
platform with 100bp paired-end reads. Variant calling, sequencing alignment, SNP calling, 
and indel calling were done using a variant calling pipeline (VCP) that was developed at 
the FIMM Technology Centre for quality control, short read alignment, and variant calling 
and annotation (186). The sequencing and bioinformatics were performed at the FIMM 
Technology Centre. 
 
Follow-up sequencing in additional CDGP cases 
 
We assessed the presence of low-frequency variants in two sets of three consecutive 
DNAH6 exons (23, 24, 25, 46, 47 and 48) in probands with CDGP (n = 135) by Sanger 
sequencing. The samples were amplified using Thermo Scientific DreamTaq Green PCR 
Master Mix (2X) (Thermo Fisher Scientific Inc, Waltham, MA) according to the 
manufacturer’s instructions. Primers were designed with OligoArchitect™ Online v4.0 
(Sigma Aldrich, St Louis, MO), and the corresponding oligonucleotides were ordered 
from Sigma Aldrich. The primer sequences were as follows (5’ to 3’):  23F: 
CCATGACCAGTATAATTG, 23R: TATGCTTAGAGTGAGAAT, 24F: 
ATAGTGGAATGTCAATAG, 24R: ATGTTTCTTAAATATGTGAT, 25F: 
GTAACTCACACTCACATT, 25R: TGTCAGAGCATTAGAATT, 46F: 
TTGCTATGTTAGAACTTC, 46R: AATACAAAGGAAACCAAT, 47F: 
TATCTACTATGCTGACAT, 47R: TCTCTATATGAATAAATTCCT, 48F: 
TTATTGAAATGACACAAC, 48R: GAGAATGGACTAATACAG. We used the 
following cycling conditions:  95°C for 1 min, 35x (95°C for 30s, 52°C for 25s, 72°C for 
30s), and 72°C for 10min. The samples were purified with ExoSAP-IT® (Affymetrix, 
Santa Clara, CA) according to the manufacturer’s instructions, and were then capillary-
sequenced by the Genome Analyzer II (Illumina, San Diego, CA) platform. Sequence 
analysis was performed with novoSNP3.0.1 (187). We used the UCSC genome browser 
(hg19) (188) as a reference sequence. 
 
4.9 Variant filtering and analysis (Study IV) 
 
We only considered variants falling within the bait region of 79-124 Mb. We prioritized 
variants with predicted consequences that affect protein structure (nonsynonymous, splice 
site, frameshift or premature stop codons) or fell in the untranslated regions upstream or 
downstream of the gene (5’ or 3’ UTRs) or were intronic. Variants in family 1 were often 
prioritized since this is a large pedigree consisting of 15 individuals, 9 of whom were 
affected, that contributed the most to the linkage finding (144). By definition, CDGP is 
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present in around 2% of the general population in whom puberty begins 2 SD later than 
the population mean, so the predisposing variant or variants are expected to be present in 
the Finnish population at a low frequency. Additionally, since the penetrance of the 
causative allele(s) is unknown, we chose to include variants with a lenient allele frequency 
threshold of 10% or less. 
 
First, we examined whether family 1 shared identical variants or different variants in the 
same gene with known 1000G frequencies of <10% with any of the other families. Only 
genes with variants in 5 or more families were considered. Second, we repeated this 
analysis for variants of unknown frequency. Without frequency information to use as a 
filter, we prioritized variants found in family 1. Last, we considered genic variants 
transmitted from either parent because bilineal inheritance could not be ruled out 
completely. To do this, we extracted variants transmitted from either parent at < 10% in 
1000G and looked for identical variants or different variants in the same gene that were 
shared by family 1 and at least 4 others.   
 
Variants of interest were followed up in several populations to confirm that their 
frequencies are less than 10%. We looked at American of European descent (Exome 
Variant Server; http://evs.gs.washington.edu/EVS/) and the Finnish (FIN-1000G and 
SISU) population to confirm their rarity. To investigate the potential deleteriousness of 
these variants, we examined SIFT (189) and PolyPhen (Polymorphism Phenotyping; 
http://genetics.bwh.harvard.edu/pph2/) (190) scores for each variant using the Variant 
Effect Predictor (191) (http://useast.ensembl.org/info/docs/tools/vep/index.html). SIFT 
and PolyPhen predict whether a codon which alters the amino acid affects protein 
structure and function. We also examined each variant’s score in RegulomeDB 
(http://regulome.stanford.edu/index), which identifies DNA features and regulatory 
elements in intergenic regions and assigns each variant a score which reflects its predicted 
ability to disrupt transcription factor binding. 
 
Candidate gene analysis 
 
A change in important regulatory element sequences affecting gene expression might be 
another way that a variant could impart a delay on pubertal onset. Thus, we created a list 
of plausible candidate genes within the linked region of 79-124 Mb on chromosome 2 
using Ensemble Biomart (http://www.ensembl.org/biomart/martview/). We focused on 
genes annotated with appropriate gene ontology (GO) terms relating to puberty, sexual 
maturation, and growth (Table 5). We also manually searched each gene on the list from 
AceView (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/) and PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) for additional evidence of involvement in puberty.  
This resulted in a short list of the best functional candidates that had evidence of 
involvement in both reproduction and growth or are directly involved in the HPG axis. 
The genes on this short list were GLI2, PAX8, INHBB, KDM3A, NPHP1, BCL2L11, 
MERTK, and IL1B. 
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Next, we looked at the possible regulatory regions surrounding these 8 best functional 
candidate genes. To do this, we looked at transmitted variants within 400kb around these 
genes (200kb from each gene’s start and terminus). We used RegulomeDB to see if shared 
variants in these regions potentially affect protein regulation by altering transcription 
factor binding sites. 
 
AAM-associated region near rs6758290 
 
A recent genome-wide association study pinpointed a variant associated with normal 
variation in age at menarche (rs6758290 at 105.8 Mb) (148), which falls in the region of 
linkage on chromosome 2. We investigated whether low-frequency variants in LD with 
rs6758290 show evidence for involvement in pubertal delay in our CDGP families. The 
LD block (r2 ≥ 0.1) surrounding this marker extends approximately 500 kb upstream and 
300 kb downstream from rs6758290 in European populations, so we extracted all variants 
from 105,364,800 – 106,164,800 (GRCh37) along chromosome 2 and looked for 
transmitted shared variants in our families. We also looked at the RegulomeDB score for 
all shared non-exonic variants. 
 
Simulation analysis 
 
Six variants in DNAH6 were found in 10 out of 13 CDGP probands. These six low-
frequency variants were predicted to affect the protein’s structure (five nonsynonymous 
amino acid changes and one stop codon). Using the SISu exome data, we investigated the 
probability of finding protein-altering variants in 10 out of 13 random sets of Finnish 
individuals.  We first detected the number of nonsynonysmous or stop codons in DNAH6 
in Finnish SISu exomes as part of the Exome Aggregation Consortium (ExAC) browser (n 
~5,000). There were a total of 82 variants, including 79 SNPs and 3 indels, of which 29 
were nonsynonymous variants and one was a stop-gain variant in Variant Effect Predictor 
(VEP; http://grch37.ensembl.org/Homo_sapiens/Tools/VEP). Many of the Finnish SISu 
individuals had missing genotypes for one or more of these variants, so they were 
removed (final n = 2,028). One variant had a high alternative allele frequency (0.96), so it 
was flipped.  We then ran a simulation by randomly selecting 13 individuals and counting 
how frequently 10 of those individuals contained at least one of the 30 protein-altering 
variants. We ran the simulation with 10,000 and 100,000 iterations. 
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Table 5.   Candidate genes on chromosome 2 between 79-124 Mb annotated with GO 
terms involving growth and reproductive function (Study IV). 
 
Gene Position 
(Mb) on 
chr 2 
General Function (Aceview) GO term(s) 
BCL2L11 111.8 Apoptotic activator Development of primary sexual 
characteristics, developmental 
process involved in reproduction, 
gonad development, multicellular 
organism reproduction, 
reproduction, sexual reproduction, 
regulation of growth, response to 
growth factor stimulus 
GLI2 121.5 Mediator of Sonic hedgehog (Shh) 
signaling, embryogenesis including 
pituitary development 
Developmental process involved in 
reproduction, reproduction, growth, 
developmental growth 
IL1B 113.5 Cell proliferation, differentiation, and 
apoptosis 
Reproduction, growth factor 
activity, growth factor receptor 
binding 
INHBB 121.1 Inhibin beta B subunit joins the alpha 
subunit to form a pituitary FSH secretion 
inhibitor 
Cellular process involved in 
reproduction in multicellular 
organism, development of primary 
sexual characteristics, 
developmental process involved in 
reproduction, gonad development, 
multicellular organism reproduction, 
positive regulation of gonadotropin 
secretion, regulation of 
gonadotropin secretion, 
reproduction, sexual reproduction, 
negative regulation of gonadotropin 
secretion, regulation of follicle-
stimulating hormone secretion, 
growth, growth factor activity 
KDM3A 86.6 Hormone-dependent transcriptional 
activation 
Cellular process involved in 
reproduction in multicellular 
organism, developmental process 
involved in reproduction, 
multicellular organism reproduction, 
reproduction, sexual reproduction 
MERTK 112.6 Receptor tyrosine kinase that transduces 
signals from the extracellular matrix into 
the cytoplasm by binding to several 
ligands. Induces phosphorylation of 
MAPK1. Autosomal recessive retinitis 
pigmentosa 
Development of primary sexual 
characteristics, developmental 
process involved in reproduction, 
multicellular organism reproduction, 
reproduction, sexual reproduction 
NPHP1 110.9 Control of cell division, as well as in cell-
cell and cell-matrix adhesion signaling, 
likely as part of a multifunctional complex 
localized in actin- and microtubule-based 
structures 
Cellular process involved in 
reproduction in multicellular 
organism, developmental process 
involved in reproduction, 
multicellular organism reproduction, 
reproduction, sexual reproduction 
PAX8 113.9 Thyroid follicular cell development and 
expression of thyroid-specific genes 
Response to gonadotropin stimulus, 
cellular response to gonadotropin 
stimulus 
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5 Results and Discussion 
5.1 rs7759968 and rs314277 at LIN28B (Studies I-III) 
 
All three of our GWA approaches were successful for detecting common variants in the 
Finnish and European populations. In particular, each study picked up variants near the 
gene LIN28B. In the first study, investigating growth during late adolescence in the 
Finnish population, we showed that the G allele at rs7759938 associated not only with 
growth from age 14 to adult, but also tagged an effect delaying the pubertal growth spurt. 
We saw the same association when we expanded the study population to Europeans within 
the EGG Consortium in Study II. In Study I, NFBC1966 was used as the discovery cohort, 
with follow-up association tests in YFS. Both of these cohorts also contributed to the 
discovery GWA in Study II. 
 
Table 6. Association results of GWA of pubertal growth from age 14 to adult for 
rs7759938 and rs314268 at the LIN28B locus for NFBC1966 and YFS in females and 
males (Study I). 
 
NFBC1966 Females YFS Females 
SNP Allele N Beta (SE) P N Beta (SE) P 
rs7759938 G 2242 0.16 (0.032) 7.2 x 10
-7 
664 0.17 (0.058) 0.004 
rs314268 G 2240 0.14 (0.032) 1.4 x 10
-5 
666 0.14 (0.058) 0.02 
NFBC1966 Males NFBC1966 Males 
rs7759938 G 2068 0.093 (0.033) 0.005 569 0.14 (0.066) 0.03 
rs314268 G 2065 0.095 (0.033) 0.004 570 0.12 (0.066) 0.07 
 
Specifically, in Study I, 5 markers in a single LD block spanning 111 kb on chromosome 6 
were significantly associated with late pubertal growth (the difference in height SDS 
between age 14 and adulthood; P < 5 x 10
-7
, n = 4,321 Finns). These markers covered the 
5’ end and upstream region of the gene LIN28B. Follow-up analysis of the leading SNP, 
rs7759938, and a proxy, rs315268, in YFS yielded further support for the locus (combined 
P for rs7759968 = 5.0 x 10
-11
, n = 5,562 Finns; Table 6), and the strongest associated 
marker explained ~1% of the total phenotypic variation in females and 0.5% in males. In 
Study II, rs7759938 also associated with late pubertal growth (P = 3.9 x 10
-9
, n = 8,863 
Europeans), with a stronger signal seen in females than in males.  
 
The amount of growth during puberty might be related to the timing of puberty, since 
individuals maturing early tend to complete growth and reach their final height earlier than 
late-maturing individuals. The effect of rs7759938 on late pubertal growth might thus be 
due to an effect on the timing of the pubertal growth spurt. In Study I, we addressed this 
question by looking at growth between ages 9 and 12, a proxy measurement for the timing 
of the onset of the growth spurt, and found that the G allele of rs7759938 did associate 
  
 
 
70 
with later onset of the growth spurt (decreased growth during early puberty in both males 
and females, P = 1.7 x 10
-4
). Thus, rs7759938 (G), the leading marker at the LIN28B 
locus, associates with a lag in growth in early adolescence followed by an increase in 
growth in late adolescence, consistent with the hypothesis that this locus tags a delay in 
the onset of the pubertal growth spurt. 
 
Additionally, in this study as well as in four other studies which were published as Study I 
was under preparation (146–149), the allele associated with later onset of the pubertal 
growth spurt also associated with later age at menarche (in Study I: β = 0.124, SE = 0.023, 
P = 8.3 x 10
-8
, n = 4,379 Finns). Both the growth spurt and menarche are secondary 
manifestations of puberty, occurring after central activation in the hypothalamus. To 
clarify whether rs7759938 might have distinct effects on pubertal growth and menarcheal 
timing or reflect the same underlying mechanism, we performed multiple regression 
analysis including both the genotype at rs7759938 and height growth from 9-12 years of 
age (as a proxy for early pubertal growth) into the model in Study I. This resulted in a 
major reduction of the association signal of rs7759938 with AAM (β = 0.046, SE = 0.03, 
P = 0.13, n = 1,932 Finns), showing that the effects of this locus on the timing of the 
pubertal growth spurt and AAM are likely not independent and are probably mediated 
through a common underlying mechanism. 
 
Further evidence for LIN28B as a regulator of central pubertal onset came from Study III, 
since LIN28B was the most robustly associated locus in the combined analysis of Tanner 
male genital and female breast staging, both early markers of pubertal onset (Table 7). In 
Study III, only rs314276 (P = 1.6 x 10
-8
; n = 9,915 Europeans) near LIN28B reached 
genome-wide significance in the combined male and female analysis of Tanner female 
breast and male genital stage. Again, the association was more significant in females (β 
(SE) = 0.087 (0.017), P = 3.7 x 10
-7) than in males (β (SE) = 0.064 (0.024), P = 0.0085). 
Because variation at the LIN28B locus associates with multiple secondary pubertal traits in 
both boys and girls, it appears that this locus may be an important part of the switch which 
triggers central activation of pubertal onset in both sexes. 
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Table 7.   Loci significantly associated with pubertal growth and timing in studies I-III. M, males; F, females; H, height; AAM, age at 
menarche; BMI, body mass index. 
 
Nearby gene SNP P N Population Phenotype Sex 
Previously 
associated related 
trait 
Study 
LIN28B rs7759938 5.0 x 10
-11
 5,038 Finnish Height change SDS (14-adult) M + F H, AAM I 
LIN28B rs7759938 3.9 x 10
-9
 8,863 European Height change SDS (14-adult) M + F H, AAM II 
LIN28B rs314276 1.6 x 10
-8
 9,915 European Tanner pubertal stage M + F H, AAM III 
ZBTB38 rs6764769 4.6 x 10
-10 
13,960 European Height SDS at age 10 and 12 M + F H II 
PXMP3 rs7846385 5.3 x  10
-10 
13,942 European Height SDS at age 10 and 12 M + F H, AAM II 
EFEMP1 rs1346789 1.2 x 10
-8 
13,960 European Height SDS at age 10 and 12 M + F H II 
CABLES1 rs6507528 1.3 x 10
-8 
13,160 European Height SDS at age 10 and 12 M + F H II 
ADAMTSL3 rs1365198 1.5 x 10
-8 
13,946 European Height SDS at age 10 and 12 M + F H II 
GNA12 rs960273 5.2 x10
-4
 6,986 European Height SDS at age 12 M H II 
ADCY rs1172294 1.0 x 10
-8 
10,799 European Height change SDS (8-adult) M + F H, BMI II 
VGLL3 rs7628864 3.2 x 10
-9 
5,756 European Height change SDS (8-adult) F AAM II 
Genome-wide significant after the addition of follow-up samples 
MAPK3 rs4788196 9.5 x 10
-11 
18,737 European Height SDS at age 10 and 12 M + F - II 
MKL2 rs246185 8.9 x 10
-9
 3,977 European Tanner pubertal stage M AAM III 
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In each of these three studies, the effect at the LIN28B locus was stronger in girls than in 
boys. At first, we hypothesized that the difference in effect could be due to the fact that the 
underlying phenotype in Studies I-II (the relative height difference between age 14 and 
adult) differed between males and females since girls enter puberty an average of two 
years prior to boys. Girls reach average PHV at around 12 years of age, while this occurs 
in boys at an average age of 14 years. Thus, it could be that the difference in effect size 
reflects the fact that measuring growth between 14 and adult targets a slightly later phase 
of the growth curve in girls as it does in boys. However, since the effect at this locus on 
breast development also appears to be stronger than the effect on male genital 
development, it seems likely that these observations reflect a true underlying difference 
between the sexes. 
 
It is not such a leap to envision that variation at the LIN28B locus might be dealt with 
differently in males and females, via an unknown mechanism. Indeed, we found that two 
partially-correlated markers, rs7759938 and rs314277 (pairwise r
2
 = 0.26), exhibit 
independent effects on adult stature that differ in males and females. Both of these 
markers were previously associated with adult stature (29). When analysed individually in 
our Finnish samples, the markers were both associated with adult stature, but rs314277 
contributed more to adult height in females whereas rs7759938 was stronger in males. 
Subsequent analysis of rs314277 conditional on rs7759938 showed opposite effects in 
males and females, which suggests that this variant has sex-specific effects. Formal testing 
indeed revealed evidence for a sex-genotype interaction at rs314277 (P = 0.005).  
 
The effect on final height was not attenuated by controlling for AAM for either marker, 
showing that prepubertal height growth contributes to the adult stature effects for both 
markers. We analysed the effects of these variants prior to puberty by plotting the effect 
size of both markers on postnatal growth at 1-year intervals from birth to adulthood in 
NFBC1966 and HBCS (Figure 9). This revealed distinct association patterns with height 
for each marker, and also showed sex-specific association patterns. rs7759938 (G) showed 
a reduction of the effect on relative height after 9, followed by an increase in the effect 
after age 12 and 14. This marker influenced the timing of the pubertal growth spurt in both 
sexes, but whereas the male effect was stable until age 10, there was a female-specific 
reduction of effect between ages 6-9. The association pattern for rs314277 (A) across 
postnatal growth was markedly different, with a steady effect on each gender that was 
distinct, but stable across postnatal growth without any effect on the pubertal growth spurt. 
Males consistently showed negative effect sizes throughout childhood and into adulthood, 
while the effect in females was positive from age 2 and reached a P-value of 0.01 at ages 9 
and 10. Multiple regression analysis also showed suggestive evidence for a genotype-sex 
interaction for rs314277 on postnatal height growth (Table 8).  
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Table 8. Linear regression of final height of two variants at the LIN28B locus (Study I) 
separately (single regression) and including both markers in the analysis (multiple 
regression) 
 
  Males Females Combined 
  Beta 
(SE) 
P N Beta 
(SE) 
P N Beta (SE) P 
Single 
regression 
rs7759938 0.078 
(0.023) 
8 x 10
-4 
4211 0.058 
(0.023) 
0.01 4692 0.074 
(0.017) 
3 x 10
-5 
rs314277 0.028 
(0.029) 
0.35 4184 0.091 
(0.028) 
0.001 4676 0.062 
(0.020) 
0.003 
Multiple 
regression 
rs7759938 0.11 
(0.031) 
5 x 10
-4 
4176 0.021 
(0.029) 
0.48 4645 0.062 
(0.021) 
0.003 
rs314277 -0.061 
(0.039) 
0.12 4176 0.075 
(0.037) 
0.04 4645 0.011 
(0.027) 
0.69 
 
 
 
Furthermore, while regression analyses of height growth during infancy, childhood, and 
puberty did not reveal any statistically significant associations, rs314277 showed a 
positive correlation with growth during all three growth periods in females. Nominal 
evidence also supported an effect on birth length in both sexes (β =  0.058, SE = 0.025, P 
= 0.02) which might reflect an effect on fetal growth. Many of the tests performed were 
not independent, but after applying a conservative Bonferroni correction (P = 0.005) to 
account for 10 independent tests, the main findings remained significant. 
 
Thus, of two partially-correlated adult stature-associated markers at this locus, one tags a 
pubertal timing effect, while the other marks a more general growth effect. The marker 
that was not associated with pubertal timing (rs314277) showed a sex-genotype interaction 
for adult stature, and displayed a sex-specific pattern of association with height growth 
across the entire postnatal trajectory from age 2.  
 
Although the mechanism through which the LIN28B locus affects height growth 
differently in males and females is as yet unknown, sex bias may occur via sex hormones 
or sex-specific gene expression that is not mediated hormonally, for example by 
differential microRNA (miRNA) regulation (192). In fact, LIN28B, and its homolog 
LIN28A, inhibit the let-7 pathway of miRNAs, and LIN28 in turn is downregulated by let-
7 in a negative feedback loop (193), showing that it is susceptible to regulation by 
miRNAs. LIN28B and LIN28A are homologs of a key developmental regulator initially 
discovered in C. elegans, and mouse studies show that the Lin28-let-7 pathway is 
important in postnatal growth and puberty (194), indicating that the associations seen in 
human GWA studies are very likely mediated through this gene. Futhermore, let-7 targets  
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Figure 9. Linear regression evaluating the independent effects of two markers at the 
LIN28B locus on postnatal height growth. Beta estimates for the association of 
length/height is plotted at each age. Regression analyses were done in NFBC1966 and 
HBCS. Birth length was adjusted for gestational age. Males are presented in blue, while 
females are in red.  * indicates a P-value of <0.05. Adapted from Widén, et al (2010). 
 
are enriched in genes nearby height-associated markers (195), suggesting that the height 
effect of LIN28B may act through down-regulation of let-7 binding targets.   
 
5.2 rs4788196 near MAPK3 (Study II)  
 
In Study II, we again used a simple approach to model three aspects of the pubertal growth 
spurt: relative height at the take-off phase (Analysis I: height SDS at age 10 yrs in girls 
and 12 yrs in boys), the total amount of growth during puberty (Analysis II: difference in 
height SDS between age 8 and adult), and growth during late puberty as in Study I 
(Analysis III: difference in height SDS between age 14 and adult). This strategy was 
successful for detecting common genetic variants in more than 18,000 study subjects of 
European descent. In addition to LIN28B, there were 8 loci significantly associated with 
pubertal growth that were previously associated with final adult stature, AAM, or BMI 
(addressed below). While there were also many signals that fell beneath the genome-wide 
significance threshold, additional samples were only available for the follow-up of 
variants suggestively associated with Analysis I, the single height measurement. Joint 
analysis of discovery and follow-up stages robustly confirmed a single novel variant not 
previously associated with related traits (AAM, height, or BMI), rs4788196 (P = 9.49 x 
10
-11
, n = 18,737 Europeans), on chromosome 16. Subsequently, eQTL analysis in whole 
blood (174) showed that the height-increasing allele (G) at rs4788196 correlated with 
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decreased expression of MAPK3 (extracellular signal-related kinase 1, also known as 
ERK1; β =-0.45, P = 3.6 x 10-5), consistent with a mouse study linking deactivation of the 
gene with increased bone growth (196).  
 
Rare recurrent CNVs near MAPK3 on chromosome 16p11.2 have been shown to associate 
with early onset obesity (166, 167), bringing up the possibility that a CNV might mediate 
the adolescent height effect. This did not appear to be the case. The association results 
from two analyses, including and excluding CNV carriers, were nearly identical, 
suggesting that CNVs in this region do not mediate the effect on relative height. The total 
number of individuals harboring CNVs in this region from NFBC1966 and YFS was 15, 
including 3 subjects with a previously published deletion of roughly 500kb associated with 
extreme obesity (166). 
 
 
Figure 10. Linear regression of postnatal height for rs2788196 at the MAPK3 locus. * 
indicates a P-value of <0.05. Adapted from Cousminer, et al (2013). 
 
To characterize the effect of the MAPK3 variant on height growth in more depth, we 
plotted the effect size from 8 years to adult for both height and BMI, and on early 
childhood length yearly from ages 1 – 4 (Figure 10). These analyses revealed a transient 
effect on height growth for the G allele from age 4 in both sexes that was diluted by 
adulthood, with no apparent effect on BMI. Rapid growth during childhood and 
adolescence correlates with early timing of sexual maturation (2), so we also tested 
rs4788196 for association with AAM (150), and found that the height-increasing allele 
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associated with earlier menarche (P = 1.42 x 10
-4
, surpassing the Bonferroni-corrected 
significance threshold of 0.007). Thus, this locus associates transiently with increased 
childhood growth in both sexes and earlier menarche in girls, effects that are independent 
of body mass. GnRH activates the gene, providing a putative biological link between 
rs4788196 and pubertal timing (197, 198). 
 
5.3 rs246185 near MKL2 (Study III) 
 
In Study III, we were able to assess a direct measurement of male puberty for the first time 
in a genome-wide association study. Male puberty is challenging to address due to the lack 
of an easy-to-assess non-invasive marker. However, in the EGG Consortium, nearly 4,000 
boys had male genital data assessed by the Tanner pubertal development scale. While 
there were no genome-wide significant signals after the primary meta-analysis of Tanner 
genital stage data in boys, one marker at chromosome 16p13.12 (rs246185) suggestively 
associated at P = 5.0 x 10
-7
, and surpassed genome-wide significance with the addition of 
a further 208 samples from the STRIP cohort (P = 8.9 x 10
-9
). Although our follow-up 
sample was limited, we found no evidence for heterogeneity of effects between the 
discovery and follow-up studies (Cochran’s statistic Q = 0.23, P = 0.99) and sample 
characteristics (i.e., ages at phenotype measurement and Tanner stage means) were similar 
between the discovery and follow-up study subjects. 
 
While multiple potential candidate genes lie in the region, the nearest gene to rs246185, 
myocardin-like 2 (MKL2), falls 38 kb upstream from the SNP and is a transcriptional 
activator involved in cell differentiation and development. We were unable to implicate 
MKL2, though, since eQTL analyses from whole blood (175, 176), lymphoblastoid cell 
lines (178, 179), and skin and adipose tissue (179) did not reveal any links between 
genotype at the leading SNPs and nearby gene expression levels. This may be partly due 
to the lack of eQTL-gene expression studies in tissues relevant for sexual maturation, such 
as those in the HPG-axis, nor during temporally relevant periods. 
 
On the other hand, this locus falls in a predicted promoter region containing a cluster of 
TF binding sites, so a variant in the region could potentially disrupt a binding site with 
implications on the expression of a nearby gene important in the timing of pubertal 
development. Using a denser map to further investigate the region surrounding rs246185, 
we fine-mapped the region in the four cohorts which contributed to the primary male 
analysis (ALSPAC, RAINE, YFS, and TEENAGE) by imputing against the 1000 
Genomes reference set (22). Only a handful of newly imputed markers showed evidence 
for association of similar strength as the leading GWA SNP, and none were predicted to 
affect nearby gene structure. However, rs193536, (r
2 
= 0.85 with rs246185), had a slightly 
stronger association with male genital stage, and is predicted to be likely to affect TF 
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binding by the RegulomeDB web tool (173) based on multiple lines of evidence, including 
TF binding motifs, DNase footprints, and DNase peaks.  
 
We also queried additional SNPs in high LD (here defined as r
2 
> 0.6) with rs246185 but 
not present in the 1000 Genomes imputed data and detected evidence for another nearby 
marker, rs74755650 (r
2 
= 0.75 with rs246185), as potentially impacting TF binding. For 
each of these two polymorphisms (rs193536 and rs74755650), two TF binding motifs 
were predicted to be affected by variation in their target sequences based on position 
weight matrices (PWM) and footprinting, which combines genome sequence information 
with experimental data to map bound TF binding sites (199, 200). Variation at rs193536 
(r
2 
= 0.85) is predicted to affect binding of PAX-3 and ER, and variation at rs74755650 is 
predicted to affect binding of PATZ1 (also known as MAZR) and WT1, each supported 
by evidence from multiple cell types (199, 200). The consensus binding motifs at these 
sites show that the polymorphisms at the PATZ1 and PAX-3 target sequences may have 
greater impact on the ability of these factors to recognize their target sites and bind to 
DNA than the polymorphisms at the WT1 and ER binding sites. For the PATZ1 binding 
motif, the G allele is strongly preferred to a T or A variant at rs74755650, while the PAX-
3 transcription factor strongly prefers a C to an A allele at rs193536. It is therefore 
possible that variation at these TF binding sites may influence variability in nearby gene 
expression.  
 
Both PATZ1 and PAX-3 are compelling candidates as mediators of variation in the timing 
of sexual development since they are both important for morphological development 
during embryogenesis (201, 202). However, PATZ1 is both a transcriptional repressor 
(203) and activator (204) that has a critical role in spermatogenesis (205), embryonic and 
postnatal growth (201), and is a corepressor of androgen receptor-dependent transcription 
(206), which is important for normal puberty in both males and females (207). Also, both 
male and female knock-out mice for the Patz1 gene are infertile (205), indicating a 
potentially broad role for this factor in the sexual development of both sexes. Still, further 
study is needed to investigate whether rs74755650, the polymorphism predicted to affect 
PATZ1 binding, is the underlying functional variant at this locus, and which nearby gene 
it may affect. 
 
Having established a novel locus for male genital development, we wanted to assess 
whether this locus might play a role in central pubertal activation in both sexes. Thus, we 
queried our GWA data on breast development as well as previously published data on 
menarcheal timing, the pubertal growth spurt, and adult stature for association with 
rs246185. The effect on breast development was not significant, despite a consistent 
direction of effect. Still, rs1659127 (r
2 
= 0.84 with rs246185) is a previously published 
AAM SNP, so we looked up rs246185 in the complete ReproGen dataset (150) and saw 
that the T allele associated with 2.1 weeks earlier menarche (P = 1.0 x 10
-8
), consistent 
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with our data showing association between the same allele and advanced genital 
development (higher Tanner score) in boys. 
 
We also found that the same allele also associated with decreased total pubertal growth 
(Analysis II in Study II), and decreased late pubertal growth (Analysis III in Study II) 
(182).  The early cessation of growth during puberty results in shorter adult stature, 
evidenced by the significant association between rs1659127 and reduced final adult height 
(P = 1.1 x 10
-11
) (29). rs246185 also associated with adult stature, although to a lesser 
degree (P = 7.5 x 10
-6
). While adult height SNPs may affect growth during multiple 
growth periods (156, 182, 208, 209), this locus primarily affects early puberty, diminished 
growth during puberty, and shorter adult height, consistent with epidemiological 
observations (210, 211). 
5.4 Additional pubertal growth loci (Study II) 
 
In Study II, there was significant deviation from the expected P-value distributions for all 
three combined-gender analyses (I, II, and III), males and females separately for Analysis 
I (height SDS at age 10 yrs), and females only for Analysis II (difference in height SDS 
between age 8 and adult). All three models resulted in genome-wide significant loci, and 8 
loci (in addition to rs7759938 near LIN28B and rs4788196 near MAPK3, mentioned 
above) contained markers that reached P-values below the genome-wide significance 
threshold corrected for testing three primary phenotypes (P < 1.67 x 10
-8
, after genomic 
control).  
 
As previously discussed, epidemiological studies support phenotypic correlations between 
earlier pubertal timing, increased obesity and decreased final height. Indeed, there was 
substantial overlap between pubertal height growth-associated loci and these related traits 
(Figure 11). All three pubertal growth approaches detected loci which also associated 
with pubertal timing (near MAPK3, PXMP3, VGLL3, ADCY3-POMC, and LIN28B) and 8 
signals overlapped with adult stature loci (29). Also, the adult height and menarche-
associated locus at ADCY3-POMC has further been implicated in childhood (184) and 
adult obesity (183). One of our signals may be independent from the previously reported 
signal, since conditioning for the previously reported marker in partial LD with our signal 
did not attenuate the association nearby CABLES1 (rs6507528; P = 0.00011).   
 
Comparing the height effects of the leading loci in Study II longitudinally across puberty, 
we noticed that they could be divided into two groups based on their association with 
pubertal timing. One group of loci (near ZBTB38, EFEMP1, CABLES1, ADAMTSL3, and 
GNA12) did not associate with AAM, but all impacted height SDS across multiple growth 
phases, strongly and steadily from prepuberty to adulthood. These loci seem to affect 
overall growth potential, rather than specific effects during the pubertal growth phase. In 
contrast, the five variants that did associate with menarche (LIN28B, MAPK3, ADCY3, 
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VGLL3 and PXMP3) had diverse effects on the timing and tempo of growth, both before 
and during puberty.   
 
 
 
 
 
Figure 11.   Variants associated with growth during puberty have distinct association 
patterns with related traits. Some associate only with pubertal timing (MAPK3 and 
VGLL3- Study II), and some have postnatal growth effects across puberty resulting in an 
influence on final adult height (the effect tagged by rs314277 at LIN28B (Study I), 
GNA12, ZBTB38, CABLES1, ADAMTSL3, and EFEMP1- Study II). Some pubertal 
timing effects also result in adult height effects, either due to accelerated growth before 
puberty (the effect tagged by rs7759938 at LIN28B (Studies I and II) and PXMP3 (Study 
II)), or due to a reduction of height growth during the pubertal growth spurt (MKL2 
(Study III)). Only ADCY3-POMC (Study II) associated with pubertal timing, adult height, 
and an increase in adiposity. Adapted from Cousminer et al (2013). 
 
Epidemiological studies have demonstrated a developmental pattern linking taller 
prepubertal stature with earlier puberty, accelerated skeletal maturation, and shorter adult 
stature due to earlier cessation of growth. While the majority of loci did show the expected 
association between early menarche and decreased overall pubertal height growth (Table 
9), the prepubertal height effects varied for each locus. Three variants (near the genes 
MAPK3, PXMP3, and VGLL3) linked tall prepubertal stature with earlier menarche, while 
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the early puberty allele (T) at rs7759938 (LIN28B) correlated with shorter prepubertal 
height, as seen in Study I. 
 
Table 9.   Epidemiologically observed links between BMI, height growth, and puberty, 
and associations seen at individual loci (Studies I-III). 
 
Epidemiological studies also correlate early puberty with shorter adult height, presumably 
due to a shorter overall period of height growth. In contrast, two genetic studies found that 
alleles associated with early puberty may correlate with either increased or decreased 
stature (133, 150). In Study II, contradictory to the predicted pattern, at rs7846385 
(PXMP3) the early menarche allele associates with increased adult stature. A plot of the 
height growth effects longitudinally across childhood show that this is because the early-
menarche allele also associates with tall prepubertal height and a limited reduction in total 
pubertal growth. This observation agrees with a recent study suggesting that adult height 
loci mediate their effect by influencing height growth during the prepubertal period (155). 
However, we find that pubertal growth variants are associated with diverse and unique 
postnatal growth patterns, and that not all loci which influence growth during puberty also 
impact adult stature. 
 
 Pre-puberty Puberty Adult 
Epidemiological observations 
 Tall or average 
stature 
Higher BMI 
Earlier menarche 
Less pubertal growth 
Shorter final stature 
Higher BMI 
Individual genetic loci 
LIN28B 
(rs7759938 G) 
Average stature 
(females) 
Taller stature (males) 
 
Later menarche 
Later pubertal growth spurt 
Later breast development 
Later male genital 
development 
 
Taller adult stature 
(males) 
 
LIN28B 
(rs314277 A) 
Taller stature 
(females) 
No effect Taller stature 
(females) 
MAPK3 
(rs4788196 G) 
Taller stature Earlier menarche No effect 
PXMP3 
(rs7846385 C) 
Taller stature Earlier menarche 
Diminished pubertal growth 
No effect 
VGLL3 
(rs7628854 G) 
Taller stature 
(females) 
Earlier menarche 
Diminished pubertal growth 
(females) 
No effect 
ADCY3 
(rs1172294 G) 
Average stature 
Higher BMI 
Earlier menarche 
Diminished pubertal growth 
Shorter adult stature 
Higher BMI 
MKL2 
(rs246185 T) 
Average stature Earlier menarche 
Earlier male genital 
development 
Diminished pubertal growth 
Shorter adult stature 
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We also plotted the effect size of BMI SDS against six age bins across puberty in Study II, 
but only the previously published menarche and BMI signal at ADCY3-POMC was 
significantly associated with BMI. Epidemiological studies predict that this marker, 
rs1172294, would associate with increased prepubertal stature, but we did not find that to 
be the case. Still, the BMI-increasing allele (G) was associated with earlier AAM (P = 
8.64 x 10
-8
) and a decline in pubertal growth in both males and females. Thus, the links 
between prepubertal height, BMI, and pubertal timing may also vary at each locus from 
epidemiologically accepted patterns. Consistently, other variants previously associated 
with childhood obesity (184) showed a similar parallel between elevated BMI and 
diminished pubertal growth. rs3817334 (MTCH2), previously associated with adult (183) 
but not childhood BMI, also associated with the same decrease in overall pubertal growth 
despite the lack of association with body mass in childhood, suggesting the presence of 
some other shared mechanism. 
5.5 BMI and Tanner breast stage in girls (Study III) 
 
The GWA meta-analysis of Tanner female breast stage and the female and male combined 
analysis did not reveal any novel associated loci. Obesity (51) and self-assessment rather 
than clinician-assessment (212, 213) may both interfere with an accurate evaluation of 
breast development, so we excluded girls in the top 20
th
 percentile of BMI in 
contemporary cohorts and re-ran the Tanner breast stage association analysis. However, 
we observed only a slight attenuation of the effect at the LIN28B locus (full dataset, 
rs314267 β (SE) = 0.09 (0.02), 20th percentile of BMI cutoff β (SE) = 0.06 (0.03)), 
showing that obesity only slightly affected our results. We also observed a high degree of 
consistency between menarche-advancing alleles and association to advanced breast 
development, addressed below. Thus, the lack of genome-wide significant associations is 
likely due to low power rather than an incorrectly assessed phenotype.  
 
5.6 Genetic overlap of menarche loci with Tanner stage (Study 
III) 
 
Female breast and male genital development are both early markers of pubertal 
development occurring soon after central activation. Data on these phenotypes therefore 
allowed us to assess the overlap between early and late measures of pubertal development 
by evaluating the proportion of menarche signals that also associate with measures more 
closely tagging the onset of puberty. Additionally, with data on male genital development, 
we were able to assess the overlap between regulators of male and female puberty.  
 
While our data provided limited power to detect significant associations, we did see a 
deviation from the expected P-value distribution for menarche variants in both the male 
and female Tanner stage GWA meta-analysis results. When we performed regression 
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analyses comparing the association effect on pubertal timing between the AAM and 
Tanner associations, we found them to be highly consistent, with the menarche-advancing 
allele also associating with higher Tanner score and thus earlier development (females P = 
0.02, males P = 0.006, combined P = 0.0009) for most loci. In addition to LIN28B and 
MKL2, the AAM locus at TMEM38B was significantly associated with Tanner pubertal 
stage for both sexes combined (P = 1.8 x 10
-5
; significance threshold accounting for 
querying 44 SNPs = 0.001). Additionally, rs3743266 at RORA, previously a possible 
menarche locus that did not surpass genome-wide significance (150) but was associated 
with menarche in African American women (152), was associated with Tanner stage in 
our data (P = 0.0008). 
 
Thus, like the loci at LIN28B and MKL2, we find that other menarche loci are important 
for pubertal initiation in both sexes and in general tag biological effects upstream of sex-
specific effects, as evidenced by the high correlation between menarche-advancing effects 
and earlier sexual maturation in both boys and girls. While some specific alleles may have 
effects that vary between boys and girls, the majority of the overall genetic architecture 
regulating pubertal initiation is similar between them, consistent with a recent study which 
found a high degree of genetic overlap between genes involved in the first pubertal 
processes, such as increased hormone secretion, and later development of secondary sex 
characteristics (214). After our study was published, the 106 loci recently implicated as 
AAM loci (133) were queried from our Tanner GWA data, and similar results were found: 
90 of 106 menarche loci showed consistent direction of effect with the male and female 
combined Tanner data. 
5.7 Genetic overlap of BMI loci and Tanner stage (Study III) 
 
While there is a clear epidemiological correlation between higher BMI and advanced 
pubertal timing in girls, the relationship between body mass and pubertal timing remains 
controversial in boys. Most studies show obesity to be associated with earlier puberty, but 
a subset of overweight boys have pubertal delay (215). In Study III, we were able to 
address the association between BMI variants and puberty in both sexes by extracting all 
known BMI-increasing variants (n = 31 (183, 184)) from the Tanner GWA meta-analysis 
results. Regression analyses of BMI loci also associated with AAM showed that the 
majority of BMI-increasing alleles associated with earlier pubertal development, 
especially in girls (female P = 0.019). These findings are consistent with studies of BMI 
loci and menarcheal timing (150, 216). rs3817334 (T) at MTCH2, a locus suggestively 
associated with decreased growth across puberty (182) but not AAM, associated with 
advanced breast development (P = 0.0008; threshold accounting for testing 31 loci = 
0.0016; sex difference P = 0.003). 
 
Although the QQ-plot for BMI loci in the male genital analysis also deviated from the line 
of null association similarly as in females, the correlation between the previously reported 
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BMI-increasing effects and pubertal timing effects was different between boys and girls. 
While some BMI-increasing loci showed the same trend towards association with earlier 
puberty, several of these alleles robustly displayed the opposite association. For example, 
the BMI-increasing allele (A) at rs571312 (MC4R), a locus not previously associated with 
puberty, associated with delayed genital development (P = 0.0009; sex difference P = 
0.003).  Of the menarche-associated BMI alleles, the T allele at rs887912 (FANCL) also 
associated with delayed sexual development in boys, but the association was not 
significant after correction for multiple testing (P = 0.005; sex difference P = 0.004). 
These results provide the first suggestion of the genetic architecture underlying the 
epidemiological observation that a subset of overweight boys experience pubertal delay. 
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Figure 12.   Association between Tanner stage and menarche-advancing variants (left) 
and between Tanner stage and BMI-increasing variants (right) for females, males, and 
both sexes combined. Adapted from Cousminer et al. (2014). 
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5.8 Pathway analyses (Studies II and III) 
 
In Studies II and III, we performed several pathway analyses to get a glimpse of the 
biological pathways that are enriched for genes with markers associated with pubertal 
growth and Tanner puberty stage.  
 
In Study II, we performed these analyses using the g:Profiler Gene Group Functional 
Profiler tool (g:GOSt (180)) and MAGENTA GSE analyses (181). These approaches 
commonly highlighted the TGF-beta signalling pathway and pathways in cancer for loci 
identified in Analysis I (height SDS at age 10 yrs in girls and 12 yrs in boys). Whereas 
g:Profiler identified the MAPK-pathway, the GSE analysis showed enrichment of lower 
than expected P-values for genes belonging to the TOB1 pathway, but the individual 
implicated gene regions were only suggestively associated and none surpassed the 
genome-wide significance threshold. 
 
For Study III, we used MAGENTA to perform GSE analysis (181). In the combined-sex 
GWA results, pathways that were enriched for genes near or containing associated SNPs 
included aminopeptidase activity, hormone sensitive lipase (HSL) mediated 
triacylglycerol hydrolysis, and apoptosis. For the female analysis, enriched pathways 
included thyrotropin-releasing hormone receptor signalling, cardiomyopathy, cancer 
(acute myeloid leukemia, endometrial cancer, prostate cancer, and the PI3 pathway), as 
well as apoptosis and the regulation of the actin cytoskeleton. For the male-specific 
analysis, only the protease inhibitor pathway surpassed an FDR of < 0.05.   
 
These analyses picked up both expected and novel pathways. Some of the expected 
pathways involved in female breast and male genital development included apoptosis, 
which is a hallmark of tissue remodeling; hypothalamic-pituitary pathways, such as the 
TRH (thyrotropin-releasing hormone) receptor signalling pathway (thyroid hormones are 
essential for normal sexual development); and steroid hormone biosynthesis and hormone 
biosynthetic process in the secondary tier of results, which show that multiple real signals 
can be expected below the significance threshold. Also, energy metabolism was picked up 
in the analysis of both sexes, as seen by the enriched pathway HSL-mediated 
triacylglycerol hydrolysis.  Triacylglycerol provides cholesterol for steroid biosynthesis 
and is an important energy store (217). Also, in mice, targeted disruption of HSL resulted 
in male sterility (218), showing the importance of this pathway in sexual development. 
 
For the early pubertal growth analysis, we detected the TGF-beta signalling pathway, 
which is involved in many important cellular processes from cell growth and 
differentiation to homestasis. Also, we picked up the MAPK pathway, suggesting that 
other members of this pathway may be important for growth during puberty in addition to 
our novel signal near MAPK3. Finally, the TOB1 pathway was enriched for genes 
containing markers with low P values. Members of the TOB1 family regulate cell growth, 
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making it an intuitive pathway for developmental growth. Additionally, it appears to 
interact with the MAPK pathway (219, 220) and functions as a tumor suppressor (221). 
 
Notably, pathways involved in cancer were picked up for both the early pubertal height 
analysis and the sexual development analysis, providing clues towards the individual 
genes which mediate a shared involvement in pubertal timing and cancer risk. Some of the 
genes nearby the leading associated signals are known to be involved in cancer, such as 
LIN28B and MAPK3. For example, LIN28 overexpression appears to promote malignancy 
in many cancer types via repression of let-7 (222). In fact, the same genetic variant 
associated with adolescent phenotypes has also been linked with cancer severity (223). 
Also, studies link MAP-kinase expression with cancer (224), and, MAPK3 expression 
predicts outcome in hormone-treated breast cancer (225). 
 
Other large GWA studies of AAM have also performed pathway analyses. In the study 
which included approximately 80,000 women, Ingenuity pathway analysis revealed two 
functional networks consisting of 16 and 11 genes, respectively (150).  The first network 
was related to gene expression, cellular growth, and cellular function and maintenance, 
while the second was involved in lipid metabolism, small molecule biochemistry, and 
molecular transport, showing that genes involved in developmental timing are 
fundamental to basic biological processes. The subsequent AAM GWA study including 
more than 180,000 women found that menarche signals were enriched in or near genes 
underlying rare Mendelian pubertal disorders (133), despite previous failed attempts to 
find common variation in genes related to HH (135). This is consistent with another 
candidate gene study which found that genes involved in steroid hormone metabolism and 
biosynthesis (278 genes in 24,341 women) were also significantly associated with AAM 
(226). In the large AAM GWA study, genes were also enriched for pituitary development 
or function, hormonal functions, and nuclear hormone receptors, co-activators, or co-
repressors (133), similar to the results of our pathway analyses. Additionally, each of the 9 
genes in the GABA-receptor II signalling pathway contained SNPs suggestively 
associated with AAM, but below the genome-wide significance threshold. The GABA 
pathway is not unexpected; in animal models, activation of the GABAB receptor inhibits 
the secretion of GnRH from the hypothalamus (227). 
 
5.9 Genotyping of CDGP trios (Study IV) 
 
We performed genome-wide analyses to identify genetic outliers as well as detect 
previously unidentified close relationships among the families contributing to the 
previously published chromosome 2 linkage peak (144). First, analysis of identity-by-
descent (IBD) aimed to detect individuals who appeared more similar to each other than 
expected in a random population.  The IBD estimate (the proportion of alleles predicted to 
be shared by descent from a common ancestor) for all pairwise combinations of affected 
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probands was between 0.05-0.08 (0-0.08 in the unselected IA controls; 8 control pairs had 
values from 0.09-0.5 and thus one member of each pair was excluded from further 
analyses). Second, the F inbreeding coefficient was -0.03 to 0.02 (-0.06 to 0.1 in controls). 
These values indicate that the affected probands are not more closely related to each other 
than expected, nor is there a high probability of consanguinity among their recent 
ancestors. 
 
 
Figure 13.  Multidimensional scaling plot showing the 13 CDGP probands (family 1 in 
yellow, families 2-13 in blue) against a background of Finnish controls from Helsinki 
(pink) and Kuopio (red). 
 
The first three PCs were calculated and used to create a matrix for MDS against the IA 
control samples. We immediately noticed that the first versus third PC mimics a 
geographical northeast to southwest axis (Figure 13), with individuals from the Kuopio 
region at the upper part of the graph, and individuals from Helsinki spread towards the 
lower part. The Finnish controls from Kuopio and Helsinki heavily overlap, in 
concordance with the post-World War II migration of Finns into the capital region (228). 
Although a couple of the probands lie close to one another, in general they all fit 
homogenously within the background of these controls, so we can conclude that none of 
the probands were either outliers or more closely related than previously expected. 
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5.10 Sequencing of CDGP probands and affected parents (Study 
IV) 
 
Targeted sequencing of chr 2: 79-124 Mb was performed in 26 samples (the affected 
proband and their suspected affected parent). The parent classified as affected was equally 
the proband’s mother (n=7) or father (n=6). The mean coverage depth in the target region 
across all samples was 60.6X and in the protein-coding regions was 41X, with an average 
of 44,826,375 reads per sample. On average, 98.2% of reads aligned to the reference 
genome, and in the targeted region, 82.2% of annotated exons (Ensembl protein-coding 
genes, n = 229) were covered at least 10X. 
 
5.11 DNAH6 (Study IV) 
 
Of the gene-centered analyses, low-frequency variants following the expected 
transmission pattern were found in three genes (DNAH6, KDM3A, and 
AC013402.2/LOC150568). Low-frequency variants were inherited from either parent 
within the gene DDX18, but some of these turned out to be fairly common in the Finnish 
population (MAF ~0.18). However, only DNAH6 (Dynein, Axonemal, Heavy Chain 6), 
contained variants that met frequency and sharing criteria and had predicted protein-
altering consequences, although these variants wee transmitted from both the affected and 
unaffected parents. DNAH6 harbored 6 variants in the top 13 families at low frequency 
with predicted stop or missense codons (Table 10). All 6 variants were present at less than 
~6% in the Finnish population. In family 1, rs184604697 was transmitted from the 
affected parent to the proband and resulted in a premature stop codon (c.7689C>A, 
p.Tyr2563Ter).  Two of the other 5 variants shared by other families were predicted to 
result in changes that would be damaging or deleterious by SIFT and/or PolyPhen-2, 
although these variants were equally likely to be transmitted from the affected parent or 
the alternative parent.  The six variants were located in two sets of three consecutive exons 
(exons 23-25 and 46-48). 
 
These 6 exons were chosen for follow-up sequencing in an additional 135 Finnish CDGP 
patients (Table 11). We detected 6 variants in these samples, 5 of which were seen in the 
top 13 families. The stop variant seen in family 1 was not detected in other CDGP 
probands. One novel mutation was observed that was not seen in the Finnish population 
controls. However, none of the variants were enriched in the CDGP probands compared to 
Finnish controls.  Unfortunately, there was no data available on pubertal timing for the 
Finnish population sample to check for delayed puberty in carriers of these variants. 
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Table 10.    Variants in DNAH6 found in the CDGP families (Study IV). 
 
Variant Position on 
chr 
2(GRCh37)
 
Consequence Predicted 
Effect 
(SIFT/PolyPhen) 
Family Transmission 
rs184604697 84926729 Stop gained 
c.7689C>A, 
p.Tyr2563Ter 
NA Family 
1 
Affected parent 
rs61743118 84846930 Nonsynonymous 
c. 3694A>G, 
p.Met1232Val 
Tolerated (1) / 
benign (0.002) 
Family 
2 
Family 
5 
Family 
6 
Family 
11 
Affected parent 
(Families 6, 11), 
other parent or de 
novo (Families 2, 
5) 
rs146306207 84926746 
Nonsynonymous 
c.7706G>A, 
p.Arg2569His 
Deleterious (0)/ 
probably damaging 
(0.958) 
Family 
4 
Other parent or de 
novo 
rs61733547 84848596 
Nonsynonymous 
c.3992G>A, 
p.Arg1331His 
Tolerated (0.1)/ 
benign (0.023) 
Family 
8 
Family 
13 
Affected parent 
(Family 8), other 
parent or de novo 
(Family 13) 
rs114514726 84924894 
Nonsynonymous 
c.1636G>A, 
p.Val546Ile 
Tolerated (0.89)/ 
unknown 
Family 
8 
Other parent or de 
novo 
rs200844717 84928399 
Nonsynonymous 
c.7997C>A, 
p.Ser2666Tyr 
Deleterious (0)/ 
probably damaging 
(0.998) 
Family 
9 
Family 
13 
Affected parent 
(both) 
 
DNAH6 encodes a dynein which functions as a microtubule-associated motor protein. 
Dyneins can be axonemal, providing the motive force for cilia and flagella, or 
cytoplasmic, where they assist intercellular movement and cytoskeletal remodeling (229). 
Although this particular gene is predicted by similarity-based approaches to localize in the 
cilium axoneme (http://www.uniprot.org/), there is a potential role for dyneins in steroid 
hormone metabolism via cytoskeletal trafficking of substrates (230), and heavy chain 
dyneins are expressed in both the brain and testis (231). DNAH6 is a large gene spanning 
300kb, and the largest of four isoforms is made up of 4,158 amino acid residues. The stop 
codon transmitted in family 1 is predicted to truncate a large portion of the protein, 
including several ATP-binding motor subunits and the microtubule-binding stalk, but the 
functional implication of this truncation is not known. Not surprising for a gene of its size, 
a substantial amount of variation has been documented within the gene, including 58 stop 
codons. Furthermore, when we ran simulation analyses, we found that approximately 13% 
of the time, 10 or more nonsynonymous or stop codons could be found in random sets of 
13 Finnish individuals from the SISu exome dataset, showing that the high frequency of 
protein-altering variants in DNAH6 in our CDGP probands is likely due to chance. 
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Table 11.     Frequencies of DNAH6 variants in the 1000G population, in the SISu 
Finnish population, and in a set of 135 unrelated Finnish CDGP patients, showing that 
these variants are not enriched in Finns or in subjects with pubertal delay. 
 
Variant Global 1000G 
frq 
SISu exome 
frq  
CDGP frq (n variant alleles/ total 
alleles) 
P
 
rs184604697 0.001 0.004 0 NA 
rs61743118 0.011 0.052 0.049 (12/246) 0.87 
rs146306207 0.001 0.009 0.015 (4/270) 0.53 
rs61733547 0.026 0.047 0.049 (10/204) 1.0 
rs114514726 0.017 0.029 0.02 (5/246) 0.68 
rs200844717 NA 0.01 0.008 (2/252) 1.0 
 
5.12 Menarche-associated region surrounding rs6758290 (Study 
IV) 
 
We also investigated a new locus associated with AAM that falls in the region under the 
chromosome 2 linkage signal, tagged by rs6758290 at 105.8 Mb (133). Although we 
examined our families for shared variants in this region, our results did not detect low-
frequency mutation that would explain the tendency toward pubertal delay, in part due to 
the lack of publically available frequency data for part of this region. With access to raw 
sequencing data from the SISu exome project, we were able to determine that this region 
is likely difficult to sequence. In the SISu data, only one variant in LD with rs6758290 
could be detected, and it had a low call rate of 19% and an average read depth of 2. In our 
CDGP subjects, however, SNPs in this region appear to have been sequenced successfully, 
with an average call depth across all families of 13 – 54 reads per marker. While several of 
these variants were shared among the CDGP probands, none were predicted to be protein-
damaging or to affect nearby gene regulation. Of these variants, 3 did have population 
frequency data, and all were common in the Finnish population, with a MAF of ~0.2. 
 
While we could not detect compelling evidence for variation predisposing pubertal delay 
in our study, this region remains an interesting candidate for future study.  The nearest 
gene to the AAM signal is GPR45, which is a G protein-coupled receptor. Little is known 
about the gene, but a BlastP search (in AceView; 
http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/) showed that the most closely 
related gene in C. elegans is npr-1, a neuropeptide receptor gene that is homologous to the 
mammalian neuropeptide Y (NPY) receptor. NPY appears to have an inhibitory function 
in the HPG axis, restraining the onset of puberty (232). Also, NPY levels were higher in 
girls with CDGP than girls with normal pubertal timing in one study (233), suggesting that 
it may play an important role in pubertal delay if deregulated.  
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5.13 Other variant detection approaches (Study IV) 
 
The other approaches taken to detect variants in this study that might predispose pubertal 
delay were not successful. While many genes contained shared transmitted variants with 
no frequency annotations in the top 5 families, little data could be gathered to prioritize 
any of these as plausible targets for follow-up studies. Most nonsynonymous variants were 
not predicted to be protein-damaging, and many apparently shared variants were flagged 
as suspect or found in multiple genomic locations, suggesting that these regions are 
difficult to sequence correctly, and that future improvements in sequence annotation is 
necessary before further assessment can be made. 
 
As for regulatory variants surrounding the best functional candidate genes, nearly all 
shared variants lacked publically available frequency information and could not be 
assessed further.  For many variants, information on their potential to fall in regulatory 
regions was also limited.  In any case, verifying a regulatory variant’s interaction with 
pubertal timing is not straightforward. 
 
Many challenges exist that might affect our ability to detect susceptibility variants 
associated with CDGP. First, if the variant is regulatory, it may be quite subtle and very 
difficult to identify. Although our overall sequencing coverage was good, the causative 
mutation could lie in a gene that was not sequenced well, as difficult-to-sequence regions 
clearly exist in this part of the genome. Also, variant annotation depends on the choice of 
transcript set as well as the software used for annotation (234), so if variants were not 
annotated appropriately, they may have been excluded from further analysis. Our 
knowledge of regulatory regions of the genome is patchy at best, so the causative variant 
might lie in a regulatory region that is of unknown function or regulating a gene that is not 
an obvious functional candidate based on current knowledge. Finally, other studies have 
encountered difficulties in detecting variants under linkage signals, which suggests that 
many linkage findings may be false positive results. Thus, variation predisposing delayed 
growth and puberty remains intractable to current methods, and future advances may help 
to detect the genetic mechanisms underlying the tail late end of normal pubertal 
development. 
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6 Conclusions and future directions 
When the work in this thesis began, little was known about genetic variants which 
contribute to pubertal development in the normal population, and most genetic studies 
focused primarily on age at menarche. By taking a broad view of the pubertal phenotypes 
available, we expanded the phenotypes investigated to include measures of the pubertal 
growth spurt as well as female breast and male genital development. Utilizing growth as a 
mapping target, we showed that the menarche-associated genomic region at LIN28B 
regulates postnatal growth, with a strong influence on growth during puberty. Using a 
longitudinal approach made possible by frequent height assessments in Finnish 
population-based cohorts across adolescence, we described independent and sex-specific 
effects for several variants at this locus. These findings provided an early suggestion that 
LIN28B is an important switch regulating multiple aspects of growth and development, a 
hypothesis which was subsequently confirmed in mouse studies. LIN28B is a highly 
conserved regulator of developmental timing first seen in c. elegans, and is reciprocally 
controlled in a double-negative feedback loop by the let-7 family of miRNAs. Due to its 
complex involvement in normal cellular growth and division as well as in cellular 
transformation when overexpressed, functional work remains to be done to fully 
understand how the LIN28-let-7 pathway links developmental pathways with adult health 
outcomes in humans.  
 
By tracking genetic effects across multiple growth periods, we uncovered 10 additional 
variants significantly associated with pubertal growth, some of which also influence 
pubertal timing, adiposity, or final height. While genetically defined association patterns 
do not always follow epidemiologically predicted correlations between these traits, they 
may pinpoint the molecular mechanisms and pathways which underlie connections 
between related traits. In turn, the characterization of these pathways may provide new 
insights into the links between developmental patterns and adult health outcomes. These 
links are likely to be quite complex, and detailed functional studies are required to 
investigate each locus in depth. These studies will need to determine which nearby genes 
convey alterations in pubertal growth and timing, and how these same genes might 
influence cardiovascular health, energy metabolism, or cancer risk later in life. 
 
This work also expanded the study of the genetic architecture of puberty to include males, 
previously overlooked in genetic association studies, and in doing so shed light on the 
genetic overlap between male and female pubertal maturation. We found that while the 
leading association signals vary between the sexes, there is likely a substantial overlap 
between molecular mechanisms that regulate pubertal initiation in males and females. 
Conversely, the genetic relationship between body fatness and puberty appears to be 
partially distinct in males and females. Further studies are required to understand the 
complex sex-specific correlations between energy metabolism and pubertal timing, and 
how they differ between boys and girls. 
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Meanwhile, genetic variation which leads to pubertal delay continues to be difficult to 
detect.  In our work, we investigated a previously published locus on chromosome 2 with 
compelling evidence for a susceptibility locus linked in Finnish constitutional delay of 
growth and puberty families. Despite the advantages of studying CDGP in Finnish 
families – a relatively homogenous genetic structure, detailed phenotype data with strict 
criteria for the inclusion of family members, and a unique resource of population-based 
sequences in the SISu set – we were unable to pinpoint genomic variation that would 
predispose to pubertal delay in these families. It is possible that the causative locus was 
missed due to gaps in sequencing coverage, but it is also possible that the variant may be 
subtle, or regulatory, in nature. Thus, genetic studies attempting to localize causative 
variants under a linkage peak remain challenging, partly due to gaps in the functional 
annotation of the genome as well as limitations of current sequencing technology to deal 
with difficult-to-sequence regions. Advancements in annotation of gene functions and 
regulatory regions of the genome will be necessary for facilitating studies of complex 
phenotypes like CDGP. 
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